Livia Biancone

Formato europeo per il curriculum vitae

Informazioni personali

Nome

LIVIA BIANCONE

Indirizzo

VIA NOMENTANA, 126

Telefono

+39.06-20903737

Fax

+39.06.20903738

E-mail

biancone@med.uniroma2.it

Nazionalità

ITALIANA

Data di nascita

21.04.1960 ( ROMA )

Esperienza lavorativa

• Date (dal 7/2/2022 ad oggi )

professore ordinario di gastroenterologia

• Nome e indirizzo del datore di lavoro

Università degli  Studi di Roma  Tor Vergata-Facoltà Medicina e Chirurgia

Viale Montpellier n. 1, 00133 Roma

• Tipo di azienda o settore

Università , Policlinico Universitario

• Tipo di impiego

Professore Ordinario di Gastroenterologia

• Principali mansioni e responsabilità ricoperte

• Professore Ordinario in Gastroenterologia (MED 12 Università Tor Vergata, Roma (dal 7/02/2022)
• Dirigente Medico I livello, U.O.C. Gastroenterologia, Policlinico “Tor Vergata”, Roma
• Responsabile di Programma a valenza scientifico professionale “Diagnostica e terapie mediche delle malattie infiammatorie intestinali”, afferente alla U.O.C. Gastroenterologia, presso il Servizio di Gastroenterologia ed Endoscopia Digestiva, Dipartimento Medicina (PTV-Protocollo Generale; Prot. N. 0000267/2008 del 09/09/2008)
• Professore Ordinario in Gastroenterologia (MED 12), Università Tor Vergata, Roma (dal 07/02/2022)

              Esperienza lavorativa

• Date (da 1983 – a 1984)

Studente Interno

• Nome e indirizzo del datore di lavoro

Istituto di Clinica Medica II

• Tipo di azienda o settore

Università  degli Studi di Roma “La Sapienza”, Policlinico Universitario, Roma

• Tipo di impiego

Studente interno, Policlinico universitario

• Principali mansioni e responsabilità

Studente interno, Policlinico universitario

             Esperienza lavorativa

• Date (da 1984 – a 1988)

Medico Interno

• Nome e indirizzo del datore di lavoro

Istituto di Clinica Medica II

• Tipo di azienda o settore

Università  degli Studi di Roma “La Sapienza”, Policlinico Universitario

• Tipo di impiego

Medico Interno

• Principali mansioni e responsabilità

Medico Interno

              Esperienza lavorativa

• Date (da 1988 – a 1991)

 Visiting Scientist

• Nome e indirizzo del datore di lavoro

University  of  Medicine  & Dentistry of  NewJersey ,UMDNJ (ex  Rutgeers  University),  New Brunswick,  NJ,  USA,  

Università degli Studi di Roma “La Sapienza”..

• Tipo di azienda o settore

Division of  GI &  Hepatology (Dir. Prof K.M. Das, MD,  Ph.D, F.R.C.P.,F.A.C.P,Professor of Medicine, Microbiology& Molecular  Genetics).

• Tipo di impiego

Borsista  dell’Istituto  Pasteur-Fondazione   Cenci-Bolognetti, per ricerche all’estero,

• Principali mansioni e responsabilità

Borsista

              Esperienza lavorativa

• Date (da 1991– a 1995)

Dottoranda di Ricerca

• Nome e indirizzo del datore di lavoro

Servizio Speciale di Medicina Nucleare Clinica Medica II

• Tipo di azienda o settore

Università  La Sapienza , Policlinico Universitario

• Tipo di impiego

Dottoranda di Ricerca

• Principali mansioni e responsabilità

Dottoranda di Ricerca

              Esperienza lavorativa

• Date (da 1996)

Dottore di Ricerca

• Nome e indirizzo del datore di lavoro

Università  La Sapienza, Roma

• Tipo di azienda o settore

Università  La Sapienza , Policlinico Universitario

• Tipo di impiego

Dottore di Ricerca

• Principali mansioni e responsabilità

Dottore di Ricerca

               Esperienza lavorativa

• Date (da 1995 – a 1997)

Contratto di Insegnamento

• Nome e indirizzo del datore di lavoro

Università di Reggio Calabria, Catanzaro

• Tipo di azienda o settore

Scuola di Specializzazione in Gastroenterologia e Endoscopia Digestiva

• Tipo di impiego

Insegnamento

• Principali mansioni e responsabilità

Insegnamento

                Esperienza lavorativa

• Date (da 1999 - 2000)

Contratto per Attività Libero Professionale

• Nome e indirizzo del datore di lavoro

Università  Campus Biomedico, Roma

• Tipo di azienda o settore

Università  Campus Biomedico, Roma

• Tipo di impiego

Cattedra di Gastroenterologia

• Principali mansioni e responsabilità

Cattedra di Gastroenterologia

               Esperienza lavorativa

• Date (da 1999 – a 2000)

Contratto per  la Collaborazione ad Attività di Ricerca

• Nome e indirizzo del datore di lavoro

Università Tor Vergata, Roma

• Tipo di azienda o settore

Dipartimento di medicina Interna, settore scientifico disciplinare MED 12

• Tipo di impiego

Collaborazione ad Attività di Ricerca

• Principali mansioni e responsabilità

Collaborazione ad Attività di Ricerca

              Esperienza lavorativa

• Date (da 2000 ad 2005 )

Ricercatore Universitario, Gastroenterologa

• Nome e indirizzo del datore di lavoro

Policlinico Tor Vergata Roma

• Tipo di azienda o settore

Università degli Studi di Roma “Tor Vergata” Roma

• Tipo di impiego

Ricercatore, Gastroenterologa (MED 12)

• Principali mansioni e responsabilità

Ricercatore, Gastroenterologa (MED 12)

              Esperienza lavorativa

• Date (dal 2006 – 2021)

Professore Associato (II fascia), Gastroenterologia MED12

• Nome e indirizzo del datore di lavoro

Policlinico Tor Vergata Roma

• Tipo di azienda o settore

Università  degli Studi di Roma “Tor Vergata” Roma

• Tipo di impiego

Professore Associato

• Principali mansioni e responsabilità

Professore Associato

Esperienza lavorativa

• Date (dal 07/02/2022 – oggi)

Professore Ordinario (I fascia), Gastroenterologia MED12

• Nome e indirizzo del datore di lavoro

Università  degli Studi di Roma “Tor Vergata” Roma

Policlinico Tor Vergata Roma

• Tipo di azienda o settore

Università  degli Studi di Roma “Tor Vergata” Roma

• Tipo di impiego

Professore Ordinario

• Principali mansioni e responsabilità

Professore Ordinario

Istruzione e formazione

• Date (1984)

Laurea in Medicina e Chirurgia

• Nome e tipo di istituto di istruzione o formazione

Università degli Studi di Roma “La Sapienza”

• Principali materie / abilità professionali oggetto dello studio

Medicina e Chirurgia , Gastroenterologia

• Qualifica conseguita

Diploma di Laurea in Medicina e Chirurgia

• Livello nella classificazione nazionale (se pertinente)

• Date (1988)

Specialista in Gastroenterologia ed Endoscopia Digestiva

• Nome e tipo di istituto di istruzione o formazione

Università “La Sapienza” Roma

• Principali materie / abilità professionali oggetto dello studio

Medicina e chirurgia , Gastroenterologia

• Qualifica conseguita

Gastroenterologo

• Livello nella classificazione nazionale (se pertinente)

Capacità e competenze personali

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

Madrelingua

italiana

Altre lingue

inglese

• Capacità di lettura

eccellente

• Capacità di scrittura

eccellente

• Capacità di espressione orale

eccellente

Capacità e competenze relazionali

Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.

CAPACITA’ RELAZIONALI

Capacità e competenze organizzative  

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

CAPACITA’ E COMPETENZE , ORGANIZZATIVE,  DI GESTIONE AMMINISTRATIVA, DI GESTIONE DIDATTICA

Capacità e competenze tecniche

Con computer, attrezzature specifiche, macchinari, ecc.

UTILIZZO COMPUTER

Capacità e competenze artistiche

Musica, scrittura, disegno ecc.

SCRITTURA, DIPLOMA PIANOFORTE CONSERVATORIO V ANNO

Altre capacità e competenze

Competenze non precedentemente indicate.

REVIEWER PER RIVISTE CON IMPACT FACTOR

• Alimentary Pharmacology & Therapeutics
• Digestive and Liver Disease
• Word Journal of Gastroenterology
• Inflammatory Bowel Diseases
• Gastroenterology
• Journal of Crohn’s Colitis
• American Journal of Gastroenterology
• Digestive and Liver Disease
• Clinical Gastroenterology & Hepatology
• Journal of Clinical Gastroenterology

ATTIVITA’ EDITORIALE

*    Coordinamento editoriale IBD Watch ,  Pensiero Scientifico Editore (1997-2000).

*    World Journal of Gastroenterology 2007-2009

*    Frontiers Internal Medicine 2012

Patente o patenti

Patente di guida

Ulteriori informazioni

SOCIETA’ E GRUPPI SCIENTIFICI (MEMBRO)

*    Società Italiana di Gastroenterologia      (SIGE)(dal 1990 ad oggi).

*    Società Italiana di Medicina Interna        (SIMI)  (dal 1990-1991).

*    Gruppo Italiano per lo Studio del Colon e Retto (GISC) dal 1998 al 2004

*    Italian Group Inflammatory Bowel Disease (IG-IBD)(dal 2005 ad oggi)

*    Comitato Italiano Capsula Endoscopica (CICE) dal 2011

*    Società Italiana di Endoscopia Digestiva (SIED) dal 2009

*    European Crohn’s Colitis Organization (ECCO)(dal 2007 ad oggi)

*    American Gastroenterological Association (AGA)(dal 2011 ad oggi)

ALTRI TITOLI

• Responsabile di Programma a valenza scientifico professionale “Diagnostica e terapie mediche delle malattie infiammatorie intestinali”, afferente alla  U.O.C. , Gastroenterologia, presso il Servizio di Gastroenterologia ed Endoscopia Digestiva, Dipartimento di Medicina (PTV- Protocollo Generale; Prot. N. 0000267/2008 del 09/09/2008).
• Referente per il Congresso Nazionale della Federazione Italiana delle Malattie dell’Apparato  Digerente (FISMAD, ex SIGE, Socità Italiana di Gastroenterologia) dal 2000.
• Rappresentante dei Ricercatori Universitari, Facoltà di Medicina e Chirurgia, Università Tor Vergata, Roma (dal 2004al 2005, poi decaduta in quanto Professore Associato).
• Membro del Consiglio Direttivo (consigliere) del Gruppo Italiano per lo Studio delle Malattie

     Infiammatorie Croniche Intestinali (IG-IBD) dal 2007 al 2009.

• Membro  del  Consiglio  Direttivo della  Società  Italiana  di  Gastroenterologia (SIGE) Lazio(SIGE Lazio) dal 2010 ad  oggi (2012).
• Good Clinical Practice  (GCP)  in  trials clinici  nelle IBD conseguito nel 2007  (ultimo 2013)

     con partecipazione quale co-investigator e principal investigator, in  trials di Fase I-II-III.

• Principal investigator o co.investigator di Trials clinici multicentrici nazionali e internazionali di faseI,  II e III (>20)(ref 48,60,66,95,105).
• Membro  del  Working  Gorup della  European  Crohns’  Colitis Organization (ECCO) per la elaborazione  delle  Linee  Guida  Europee  per  la  diagnosi  e  trattamento  della  Pouchite ell’European Crohn’s Colitis Organization (ECCO) 2008 (ref. 77. JCC 2008; 2:63-92).
• Membro  del  Working  Group  della  European  Crohns’ Colitis Organization (ECCO) per la stesura di  Linee  Guida Europee per l’imaging del colon nelle IBD 2012  (JCC submitted).

PUBBLICAZIONI SU RIVISTE           

SCIENTIFICHE CON IMPACT FACTOR      Nominativo incluso fra i TIS (Top Italian Scientist)

       H-Index 51; Citazioni 11.740 da 222 documenti (fonte: scopus al    

                                                                  16.06.2024);(vedi titolo n. 65). - Author Scopus identifier: 16030647200;  

       ORCID identifier: https://orcid.org/0000-0002-9056-1957 - TIS (Top

       Italian Scientist in Biomedical Sciences): nominative incluso rank 934 (al

       28/11/2021). - Pubblicazioni: 222 Pubblicazioni in extenso, 5 lettere, 25  

       capitoli di Libri (vedi da pag 34-64). ASN: Abilitazione scientifica

       nazionale ai sensi art. 16 della legge n. 240 del 2010 per le funzioni di

       Professore universitario di prima fascia, Bando anno 2012 (DD n.     222/

       2012, ASN della durata di 9 anni, dal 16/12/2013 al 16/12/2023) per il

      settore concorsuale 06/D4 oggetto del bando (titolo n. 20). - ASN:

      Abilitazione scientifica nazionale ai sensi art. 16 della legge n. 240 del 2010

      per le  funzioni di Professore universitario di prima fascia, settore

      scientifico-disciplinare MED/12 (06/D4): (seconda abilitazione, valida dal

       03/04/2018 al 03/04/2027 Bando D.D.1532/2016)(vedi titolo n. 21,22).

Include 237 pubblicazioni (di cui 5 lettere), pubblicate su riviste scientifiche internazionali con Impact Factor o ISNN con "peer review" citate sul Science Citation Index, Current Content Life Sciences e/o Scopus, e/o ISI Web of Sciences, Impact factor (IF indicato possibili modificazioni). 1. Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, Boirivant M. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's Disease. "In vivo" state of activation and "in vitro" response to stimulation as defined by the expression of early activation antigens. Gut 1987;28:745-753. doi:10.1136/gut.28.6.745. ISSN 0017-5749 (Impact Factor 23.059). 2. Pallone F, Squarcia O, Fais S, Boirivant M, Biancone L, Tonietti G. T cell differentiation antigens expressed by peripheral blood lymphocytes in Crohn’s Disease. Boll Ist Sieroter Milan 1985; 64(5): 394-399. ISSN 0021-2547. 3. Fais S, Pallone F, Squarcia O, Biancone L, Ricci F, Paoluzi P, Boirivant M. HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clinical & Experimental Immunology 1987; 68(3): 605-612; ISSN 0009-9104 (Impact Factor 4.330). 4. Biancone L, Paganelli R, Fais S, Squarcia O, D'Offizi GP, Pallone F. Peripheral and intestinal lymphocyte activation after “in vitro” exposure to cow's milk antigens in Normal Subjects and in patients with Crohn's Disease. Clinical Immunology and Immunopathology (ora Clinical Immunology) 1987;45:491-498. doi: 10.1016/ 0090-1229 (87) 90100-0. ISSN 0090-1229 (Impact Factor 3,969). 5. Biancone L, Boirivant M, Fais S, Ricci GL, Paganelli R, Pallone F. Serum immunomodulatory factors in gastrointestinal diseases. A 30-50-Kd serum fraction in Crohn's Disease capable of modulating lymphocyte activation. Clinical & Experimental Immunology 1991; 83(3): 401-406. doi: 10.1111/j.1365-2249. 1991. tb05651. x; ISSN 0009-9104 (Impact Factor 4.330). 6. Biancone L, Wise LS, Das KM. The presence in experimental animals of a colon specific Mr 40,000 protein(s) with relevance to Ulcerative Colitis. Gut 1991; 32 (5): 504-508. doi: 10.1136/gut.32.5.504. ISSN 0017-5749 (Impact Factor 23.059). 7. Pallone F, Luzza F, Delle Fave GF Annibale B, Marcheggiano A, Biancone L, Torsoli A. Capurso L. Lansoprazole and Helicobacter pylori infection. Clinical Therapeutics 1993; 15 (Suppl B): 49-57. ISSN 0149-2918 (Impact Factor 3.393). 8. Biancone L, Das KM, Roberts AI, Ebert EC. Ulcerative Colitis serum recognizes the Mr 40 K protein on colonic adenocarcinoma cells for antibody- dependent cellular cytotoxicity. Digestion 1993; 54(4): 237-242. doi: 10.1159/000201043. ISSN: 0012-2823; (Impact Factor 3.216). 35/68 9. Roberts AI, O' Connel SM, Biancone L, Brolin RE, Ebert EC. Spontaneous cytotoxicity of intestinal ihtraepithelial lymphocytes: clues to the mechanism. Clinical & Experimental Immunology 1993; 94(3): 527-532. doi: 10.1111/j.1365-2249.1993.tb08229.x. ISSN 0009-9104.(Impact Factor 4.33). 10. Biancone L, Scopinaro F, Maletta M, Monteleone G, Luzza F, Mercantini P, Renda T, Pallone F. Circulating D dimer in inflammatory bowel disease. Italian Journal of Gastroenterology (ora Dig Liv Dis) 1994;26 (3): 116-120. ISSN: 1125-8055; (Impact Factor DLD 4.088). 11. Boirivant M, Biancone L, Pallone F. Crohn’s Disease: ethiopatogenesis. Ann Ital Chir 1994; 65(3): 261-263 (Impact Factor 0.588). 12. Luzza F, Maletta M, Imeneo M, Doldo P, Marasco R, Biancone L, Pallone F. Salivary specific IgG is a sensitive indicator of the humoral immune response to Helicobacter Pylori. FEMS Immunology and Medical Microbiology 1995;10(3-4):281-283. doi: 10.1111/j.1574-695X. 1995. tb00044.x. ISSN 0928-1995. (Impact Factor 3.166). 13. Luzza F, Imeneo M, Maletta M, Monteleone G, Doldo P, Biancone L, Pallone F. Isotypic analysis of specific antibody response in serum, saliva, gastric and rectal homogenates of Helicobacter pylori-infected patients. FEMS Immunology and Medical Microbiology 1995; 10(3-4): 285-288; doi: 10.1111/j.1574-695X.1995. tb00045.x. ISSN 0928-1995 (Impact Factor 3.166). 14. Biancone L, Mandal A, Dasgupta T, Paoluzi AO, Paoluzi P, Pallone F, Das KM. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in Ulcerative Colitis. Gastroenterology 1995;109 (1):3-12; doi 10.1016/0016-5085(95)90263-5; ISSN: 0016-5085 (Impact Factor 22.682). 15. Luzza F, Maletta M, Imeneo M, Fabiano E, Doldo P, Biancone L, Pallone F. Evidence against an increased risk of Helicobacter pylori infection in dentists. A serological and salivary study. European Journal of Gastroenterology & Hepatology 1995: 7(8): 773-776. ISSN: 0954-691X (Impact Factor 2.566). 16. Luzza F, Maletta M, Imeneo M, Marcheggiano A, Iannoni C, Biancone L, Pallone F. Salivary specific IgG in the diagnosis of Helicobacter Pylori infection in dyspeptic patients. American Journal of Gastroenterology 1995;90(10):1820-1823. ISSN:0002-9270 (Impact Factor 10.241). 17. D' Argenio G, Biancone L, Cosenza V, Della Valle N,, D’Armiento FP, Boirivant M, Pallone F, Mazzacca G. Transglutaminase in Crohn's Disease. Gut 1995; 37(5): 690-695; doi: 10.1136/gut.37.5.690. ISSN 0017-5749 (Impact Factor 23.059). 36/68 18. Luzza F, Imeneo M, Maletta M, Mantelli I, Tancrè D, Merando G, Biancone L, Pallone F. Helicobacter pylori-specific IgG in chronic haemodialysis patients: relationship of hypergastrinaemia to positive serology. Nephrology Diaysisl Transplantation 1996;11(1):120-124. ISSN 0931-0509 (Impact Factor 5.992). 19. Pietravalle P, Monteleone G, Morano S, Cristina G, De Rossi MG, Sagratella E, Biancone L, Parrello T, Oliva A, Pallone F, Di Mario U. Antineutrophil cytoplasmic antibodies are present in long standing type 1 diabetics but not correlate with selective proteinuria. Journal of Autoimmunity 1996; 9 (1): 113-117. doi: 10.1006/jaut.1996.0014. ISSN 0896-8411 (Impact Factor 7.094) 20. Signore A, Picarelli A, Chianelli M, Biancone L, Annovazzi A, Tiberi C, Anastasi E, Multari G, Negri M, Pallone F, Pozzilli P. 123I-Interleukin-2 scintigraphy: a new approach to assess disease activity in autoimmunity. Journal of Pediatric Endocrinology and Metabolism 1996; 9 (Suppl 1): 139-144. doi: 10.1515/j pem.1996. 9.s1.139; ISSN 2191-0251 (Impact Factor 1.634) 21. Luzza F, Maletta M, Imeneo G, Monteleone G, Marasco R, Biancone L, Pallone F. Evidence against colonic mucosa colonisation by Helicobacter pylori. Lack of a specific antibody response in homogenates of rectal endoscopic biopsies. Italian Journal of Gastroenterology (ora Dig Liv Dis) 1996;28(8): 447-451. ISSN: 1125-8055 (Impact Factor DLD 4.088). 22. Monteleone G, Biancone L, Marasco R, Morrone G,Marasco O, Luzza F, Pallone F. Interleukin-12 (IL-12) is expressed and actively released by Crohn's Disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112(4):1169-1178. doi: 10.1016/s0016-5085(97)70128-8; ISSN: 0016-5085 (Impact Factor 22.682). 23. Biancone L, Scopinaro F,Ierardi M, Paoluzi P, Marcheggiano A, Di Paolo MC, Porowska B, Centi Colella A, Pallone F. 99mTc-HMPAO granulocyte scintigraphy in the early detection of postoperative asymptomatic recurrence in Crohn's Disease. Digestive Diseases and Science 1997; 42 (7): 1549-1556. doi: 10.1023/a:1018843516651.ISSN: 1594-5804 (Impact Factor F 3.199) 24. Parrello T, Pavia M, Angelini IF, Monteleone G, Riegler G, Papi G, D’Incà R, Annese D, Tonelli F, Caprilli R, Pallone F and The Italian Group of the Study of the Colon and Rectum (GISC) (* Co-investigator: Biancone L). Appendectomy is an independent protective factor for ulcerative colitis:results of a multicentre case control study. The Italian Journal of Gastroenterology and Hepatology (ora Dig Liv Dis) 1997; 29: 208-213 (Impact Factor DLD 4.088). 37/68 25. Geng X, Biancone L (*first co-author), Dai HH, Lin JJC, Yoshizaki N, Dasgupta A, Pallone F, Das KM. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in Ulcerative Colitis. Gastroenterology 1998; 114(5): 912-922. doi: 10.1016/s0016-5085(98)70310-5. ISSN: 0016-5085 (Impact Factor 22.682). 26. Luzza F, Maletta M, Imeneo M, Marcheggiano A, Biancone L, Pallone F. Mucosal and systemic antibody levels against Helicobacter pylori do not parallel gastric inflammatory changes. The Italian Journal of Gastroenterology and Hepatology (ora Dig Liver Dis) 1998; 30(1):36-39 (Impact Factor DLD 4.088). 27. Biancone L, Monteleone G, Marasco R , Pallone F. Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives. Clinical & Experimental Immunology 1998; 113(2): 198-205. doi: 10.1046/j.1365-2249.1998.00610.x. ISSN 0009-9104 (Impact Factor 4.33). 28. Biancone L, Ferrieri A, Silvestri M, Pallone F. Rifaximin in inactive Crohn’s Disease: effect on the intestinal protein loss as assessed by the fecal ?1-antitrypsin clearance. Journal of Clinical Research 1998 (1): 293-301. ISSN: 2795-6172. 29. Monteleone G, Trapasso F, Parrello T, Biancone L, Stella A, Iuliano R, Luzza F, Fusco A, Pallone F. Bioactive IL-18 expression is up-regulated in Crohn’s Disease. The Journal of Immunology 1999; 163(1): 143-147. ISSN 0022-1767 (Impact Factor 5.422). 30. Viscido A, Corrao G, Taddei G, Caprilli R (a GISC* study: Frieri G, Latella G, Pimpo MT, Pallone F, Capurso L, Andreoli A, Papi C, Vernia P, Biancone L, Ciaco A, Torchio P, Tonelli F, D’Albasio G, Ficari F, Valpiani D, Rigo GP, Sturniolo GC, D’Incà R, Rossini FP, Ponti V. “Crohn’s Disease Activity Index” is inaccurate to detect the post-operative recurrence in Crohn’s Disease. A GISC* study. The Italian Journal of Gastroenterology and Hepatology (ora Dig Liv Dis) 1999; 31: 274-1279 (Impact Factor DLD 4.088). 31. Biancone L, Pallone F. Current treatment modalities in active Crohn’s Disease. The Italian Journal of Gastroenterology and Hepatology (ora Dig Liv Dis) 1999; 31(6): 508-514. (Impact Factor DLD 4.088). 32. Rubino A, Biancone L, Zardo E, Zanna V, Saya A, Ciani N, Perceptual defense mechanisms in Crohn’s Disease and panic disorder. Perceptual and Motor Skills 1999; 88 (3 Pt 1): 733-743..doi: 10.2466/pms.1999.88.3.733. ISSN 0031-5125 (Impact Factor 1.647). 38/68 33. Signore A, Chianelli M, Annovazzi A, Bonanno E, Spagnoli LG, Pozzilli P, Pallone F, Biancone L. 123I-Interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn’s Disease. Journal of Nuclear Medicine 2000: 41(2): 242-249. ISSN 0161-5505 (Impact Factor 10.057) 34. Monteleone G, Cristina G, Parrello T, Morano SD, Biancone L, Pietravalle P, Sagratella E, Doldo P, Luzza F, Di Mario U, Pallone F. Altered Ig(4) renal clearance in patients with inflammatory bowel diseases. Evidence for asubclinical impairment of protein charge renal selectivity. Nephrology Dialysis Transplantation 2000;15(4):498-501.doi:10.1093/ndt/15.4.498. ISSN 0931-0509 (Impact Factor 5.992) 35. Monteleone G, Biancone L, Wedel S, Pallone F. IL-4 hyporesponsiveness of Crohn’s Disease mucosal T lymphocytes:a response of polarised Th1 cells? Digestive and Liver Disease 2000;32(6):495-497. doi: 10.1016/s1590-8658(00)80006-7.ISSN:1594-5804 (Impact Factor 4.088). 36. Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F. Effect of rifaximin on intestinal bacterial overgrowth in Crohn’s Disease as espressed by the H2-Glucose Breath Test. Current Medical Research and Opinion 2000; 16(1): 14-20. doi: 10.1185/0300799009117003. ISSN 0300-7995 (Impact Factor 2.580). 37. Diacinti D, Del Duca P, Tomei E, Biancone L, Caprilli R. Role of the small bowel lumen/wall ratio in patients with Crohn’s disease. Ultrasound in Medicine and Biology 2000;26(Suppl 2): A117-172. ISSN 0301-5629 (Impact Factor 2.998). 38. Biancone L, Pavia M, Del Vecchio Blanco G, D'Incà R, Castiglione F, De Nigris F, Doldo P, Cosco C, Vavassori P, Bresci G, Arrigoni A, Cadau G, Monteleone I, Rispo A, Fries W, Mallardi B, Sturniolo GC, Pallone F; Italian Group for the Study of the Colon and Rectum (GISC). Hepatitis B and C virus infection in Crohn's Disease. Inflammatory Bowel Diseases 2001;7(4): 287-294. doi: 10.1097/00054725-200111000-00002. ISSN: 1078-0998 (Impact Factor 5.325). 39. Biancone L, Geboes L, Spagnoli LG, Del Vecchio Blanco G, Monteleone I, Vavassori P, Palmieri G, Chimenti S, Pallone F. Metastatic Crohn’s Disease of the forehead. Inflammatory Bowel Diseases 2002; 8(2): 101-105. doi: 10.1097/00054725-200203000-00006.ISSN 1078-0998 (Impact Factor 5.325). 40. Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F. Immunoregulation in the gut: success and failures in human disease. Gut 2002; 50 (Suppl 3): III60-III64. doi: 10.1136/gut.50.suppl_3.iii60. ISSN: 0017-5749.) (IF 23.059). 41. Biancone L, Del Vecchio Blanco G, Castiglione F, Bresci A, Pallone F, Sturniolo GC, on behalf of the GISC. Immunomodulatory drugs in Crohn’s Disease patients with Hepatitis B or C virus infection (letter). Gastroenterology 2002;122(2): 593-594.doi:10.1053/gast.2002.31602. ISSN: 0016-5085 (Impact Factor 22.682). 39/68 42. Vavassori P, Borgani P, D’Apice MR, De Nigris F, Del Vecchio Blanco G, Monteleone I, Biancone L, Novelli G, Pallone F. 3020insC mutation within the NOD2 gene in Crohn’s Disease: frequency and association with clinical pattern in an Italian population (letter). Digestive and Liver Disease 2002; 34(2):153. doi: 10.1016/S1590-8658(02)80249-3; ISSN:1594-5804 (Impact Factor 4.088). 43. Biancone L, De Nigris F, Fina D, Di Steffano F, Fantini MC, Bozzi R, Pallone F. Treatment with anti-Tumor necrosis factor-? monoclonal antibodies in Crohn's disease: Indications and treatment modalities. Giornale Italiano di Endoscopia Digestiva 2002; 25(2): 127-130. ISSN: 0394-0225. 44. Biancone L, Palmieri G, Lombardi A, Vavassori P, Monteleone I, Del Vecchio Blanco G, Colantoni A, Spagnoli L, Tonelli F, Pallone F. Cytoskeletal proteins and resident flora. Digestive and Liver Disease 2002; Suppl. 2:s34-36. doi: 10.1016/S1590-8658(02)80161-X; ISSN:1594-5804 (Impact Factor 4.088). 45. Biancone L, De Nigris F, Del Vecchio Blanco G, Monteleone I, Vavassori, P, Geremia A, Pallone F. Review article : monitoring the activity of Crohn’s Disease. Alimentary Pharmacology & Therapeutics 2002;16(S4):29-33.doi:10.1046/j.1365-2036.16.s4.18.x. ISSN: 0269-2813 (Impact Factor 8.171). 46. Biancone L, Monteleone I, Del Vecchio Blanco G, Vavassori P, Pallone F. Resident bacterial flora and immune system. Review. Digestive and Liver Disease 2002;34: Suppl 2:S37-43. doi: 10.1016/s1590-8658(02)80162-1; ISSN: 1590-8658 (Impact Factor 4.088). 47. Biancone L, Fiori R, Tosti C, Marinetti A, Catarinaccu M, De Nigris F, Simonetti G, Pallone F Virtual colonoscopy compared with conventional colonoscopy for stricturing postoperative recurrence in Crohn's Disease. Inflammatory Bowel Diseases 2003; 9(6): 343-350; doi: 10.1097/00054725-200311000-00001; ISSN 1078-0998 (Impact Factor 5.325). 48. Biancone L, Tosti C, Fina D, Fantini M, Bozzi R, De Nigris F, Pallone F, Biancone L Review article: maintenance treatment of Crohn’s Disease. Alimentary Pharmacology & Therapeutics 2003;17 (Suppl 2):31-37.doi:10.1046/j.1365-2036.17.s2.20 .x.ISSN: 0269-2813. (Impact Factor 8.171). 49. Biancone L, Palmieri G, Lombardi A, Colantoni A, Tonelli F, Das KM, Pallone F. Tropomyosin expression in the ileal pouch: a relationship with the development of pouchitis in Ulcerative Colitis. American Journal of Gastroenterology 2003; 98: 2719-2726. doi:10.1111/j.1572-0241.2003.08719. ISSN: 0002-9270 (Impact Factor 10.241). 50. Annovazzi A, Biancone L, Caviglia R, Chianelli M, Capriotti G, Mather SJ, Caprilli R, Pallone F, Scopinaro F, Signore A. 99Tc-Interleukin-2 and 99m-Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn’s Disease. European Journal of Nuclear Medicine and Molecular Imaging 2003; 30(3): 374-382. doi: 10.1007/ s00259-002-1069. ISSN: 619-7070 (Impact Factor 9.236). 40/68 51. Biancone L, Fantini M, Tosti c, Bozzi R, Vavassori P, Pallone F. Fecal ?1-Antitrypsin clearance as a a marker of clinical relapse in patients with Crohn’s Disease of the distal ileum. European Journal of Gastroenterololy & Hepatology 2003; 15: 261-266. doi: 10.1097/00042737-200303000-00009. ISSN:0954-691X (Impact Factor 2.566). 52. Caprilli R, Cottone M, Tonelli F, Sturniolo G, Castiglione F, Annese V, Papi C, Viscido A, Camma’ C, Corrao G, Biancone L. et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn’s Disease: a pragmatic, double-blind, randomized controlled trial. Alimentary Pharmacology and Therapeutics 2003;17(4):517-523.ISSN:0269-2813 (Impact Factor 8.171) 53. Biancone L, Tosti C, De Nigris F, Fantini M, Pallone F. Selective COX-2 inhibitors and relapse of Inflammatory Bowel Disease (letter). Gastroenterology 2003;125(2): 637-638. ISSN: 0016-5085 (Impact Factor 22.682). 54. Vavassori P, Borgiani P, Biancone L, D’Apice MR, De Nigris F, Del Vecchio Blanco G, Monteleone I, Monteleone G, Novelli G, Pallone F. CARD15 mutation analysis in an italian population: Leu1007fsinsC but neither Arg702Trp nor Gly908Arg mutations are associated with Crohn's Disease. Inflammatory Bowel Diseases 2004:10(2):116-121.doi:15168811.ISSN 1078-0998 (Impact Factor 5.325) 55. Biancone L, Tosti C, Geremia A, Fina D, Petruzziello C, Emerenziani S, Pallone F. Rofecoxib and early relpase of Inflammatory Bowel Disease: an open-label trial. Alimentary Pharmacology & Therapeutics 2004; 19(7): 755-764. doi: 10.1111/j.1365-2036.2004.01907. ISSN: 0269-2813 (Impact Factor 8.171). 56. De Nardo D,De Sanctis, Biancone L,Khalil J,Kroegler B,De Risi E,Franconi G,Capria A, Fontana L. Churg-Strauss syndrome development during asthma therapy with leukotriene receptor antagonists: Just a coincidental association? European Journal of Inflammation 2005; 2(3):133-139. ISSN: 1721-727X (Impact Factor 0.466). 57. Monteleone G, Monteleone I, Fina D, Vavassori P, Del Vecchio Blanco G, Caruso T, Tersigni R, Alessandroni L, Biancone L, Naccari GC, MacDonald TT, Pallone F. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005;128: 687-694.doi:10.1053/j.gastro.2004.12.042.ISSN: 0016-5085. (Impact Factor 22.682). 58. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflammatory Bowel Diseases 2005; 11(5): 421-427. ISSN 1078-0998 (Impact Factor 5.325). 59. Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Digestive and Liver Disease 2005; 37(6): 407-417. ISSN: 1590-8658 (Impact Factor 4.088). 41/68 60. Biancone L, Schillaci O, Capoccetti F, Bozzi RM, Fina D, Petruzziello C, Geremia A, Simonetti G, Pallone F. Technetium-99m HMPAO labelled leukocyte single photon emission computerised tomography (SPECT) for assessing Crohn's Disease extent and intestinal infiltration. American Journal of Gastroenterology 2005; 100(2): 344-354. ISSN: 0002-9270 (Impact Factor 10.241). 61. Spada C, Spera G, Riccioni M, Biancone L, Petruzziello L, Trincali A, Familiari P, Marchese M, Obder G, Mutignani M, Perri V, Petruzziello c, Pallone F, Costamagna G. A novel diagnostic tool for detecting functional patency of the small bowel: the given patency capsule. Endoscopy 2005; 37(9): 793-800. doi:10.1055/s-2005-870246. ISSN: 0013-726X (Impact Factor 10.093). 62. Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci G, Riegler G, Mocciaro F, Cassinotti A, Cosintino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimeca D, Cottone M, Italian Multicentric Study Group on Infliximab. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Digestive and Liver Disease 2005;37(8):577-83. doi: 10.1016/j.dld.2005.01.019. ISSN: 1590-8658 (Impact Factor 4.088). 63. Filippi L, Biancone L, Petruzziello C, Schillaci O. Tc-99m HMPAO-labeled leukocyte scintigraphy with hybrid SPECT/CT detects perianal fistulas in Crohn’s disease. Clinical Nuclear Medicine 2006; 31: 541-542. doi: 10.1097/01.rlu.0000233082.89996.3a. ISSN: 0363-9762 (Impact Factor 7.794). 64. Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C Mocciaro F. Geremia A. Calabrese E. Cottone M. Pallone F. Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study. Gut 2006; 55: 228-233. doi: 10.1136/gut.2005.075937. ISSN: 0017-5749 (Impact Factor 23.059). 65. Biancone L, Cretella M, Tosti C, Palmieri G, Petruzziello C, Geremia A, Calabrese E, Pallone F. Local injection of Infliximab in the postoperative recurrence of Crohn’s Disease. Gastrointestinal Endoscopy 2006; 63: 486-492. doi: 10.1016/j.gie.2005.08.047. ISSN: 0016-5107 (Impact Factor 9.427). 66. Monteleone I, Monteleone G, Fina D, Petruzziello C, Calabrese E, Biancone L, Pallone F. A Functional Role of Flip in conferring resistance of Crohn’s Disease lamina propria lymphocytes to FAS-mediated apoptosis. Gastroenterology 2006; 130: 389-397. doi: 10.1053/j.gastro.2005.10.021. ISSN: 0016-5085 (Impact Factor 22.682). 67. Biancone L, Gionchetti P, Blanco Gdel V, Orlando A, Annese V, Papi C, Sostegni R, D'Incà R, Petruzziello C, Casa A, Sica G, Calabrese E, Campieri M, Pallone F. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Digestive and Liver Disease 2007; 39(4): 329-337. doi: 10.1016/j.dld.2007.01.012. ISSN: 1590-8658. (Impact Factor 4.088). 42/68 68. Biancone L, Calabrese E, Petruzziello C, Onali S, Caruso A, Palmieri G, Sica G, Pallone F. Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease. Inflammatory Bowel Diseases 2007; 13(10): 1256-1265. doi: 10.1002/ibd.20199. ISSN 1078-0998 (Impact Factor 5.325). 69. Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nature Clinical Practice Gastroenterology & Hepatology 2007; 4(2):78-91. doi:10.1038/ncpgasthep0695. ISSN: 1759-5045 (Impact Factor 10.508). 70. Borgiani P, Perricone P, Perricone C, Ciccacci C, Romano S, Novelli G, Biancone L, Petruzziello C, Pallone F. Interleukin-23R Arg381Gln is associated with susceptibility to Crohn's disease but not with phenotype in an Italian population (letter). Gastroenterology 2007; 133(3): 1049-1051.doi: 10.1053/j.gastro.2007.07.013. ISSN: 0016-5085 (Impact Factor 22.682). 71. Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, Viscido A, Annese V, Riegler G, Meucci G, Marrollo M, Sostegni R, Gasbarrini A, Paralta S, Prantera C, Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Alimentary Pharmacology & Therapeutics 2007; 26(5): 747-756. doi: 17854611. ISSN: 0269-2813 (Impact Factor 8.171). 72. Biancone L, Onali S, Calabrese E, Petruzziello C, Zorzi F, Condino G, Sica GS, Pallone F. Non-invasive techniques for assessing postoperative recurrence in Crohn's disease. Digestive and Liver Disease 2008; Suppl 2: S265-S270. doi: 10.1016/S1590-8658(08)60536-8. ISSN: 1590-8658 (Impact Factor 4.088). 73. Biancone L, Calabrese E, Palmieri G, Petruzziello C, Onali S, Sica GS, Cossignani M, Condino G , Das KM, Pallone F. Ileal lesions in patients with ulcerative colitis after ileo-rectal anastomosis: relationship with colonic metaplasia. World Journal of Gastroenterology 2008; 14(34): 5290-5300. doi: 10.3748/wjg.14.5290. ISSN: 1007 9327 (Impact Factor 5.742). 74. Sica GS, Iaculli E, Benavoli D, Biancone L, Calabrese E, Onali S, Gaspari AL. Laparoscopic versus open ileo-colonic resection in Crohn's disease: short- and long-term results from a prospective longitudinal study. Journal of Gastrointestinal Surgery 2008; 12(6): 1094-1102. doi: 10.1007/s11605-007-0394-6. ISSN: 1091-255X (Impact Factor 3.452). 75. Das KM, Biancone L. Is IBD an autoimmune disorder? Inflammatory Bowel Diseases 2008, Suppl 2: 97-101. doi: 10.1002/ibd.20723. ISSN: 1078-0998 (Impact Factor 5.325). 43/68 76. Caprioli F, Stolfi C, Caruso R, Fina D, Sica G, Biancone L, Pallone F, Monteleone G. Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammation. Gut 2008; 57(12): 1674-1680. doi: 10.1136/gut.2008.149286. ISSN: 0017-5749 (Impact Factor 23.059). 77. Biancone L, Michetti P, Travis S, Escher J, Moser G, Forbes A, Hoffmann J, Dignass A, Gionchetti P, Jantschek G, Kiesslich R, Kolacek S, Mitchell R, Panes J, Soderholm J, Vucelic B, Stange E. European evidence-based Consensus on the management of ulcerative colitis: Special situations. Journal of Crohn’s and Colitis; 2008: 63-92. doi:10.1016/j.crohns.2007.12.001. ISSN:1873-9946 (Impact Factor 9.071). 78. Perricone C, Borgiani P, Romano S, Ciccacci C, Fusco G, Novelli G, Biancone L, Calabrese E, Pallone F. ATG16L1 Ala197Thr is not associated with susceptibility to Crohn's disease or with phenotype in an Italian population (Letter). Gastroenterology 2008; 134(1): 368-370. doi: 10.1053/j.gastro.2007.11.017. ISSN: 0016-5085 (Impact Factor 22.682). 79. Stroppa I, Grasso E, Paoluzi O Razzini C, Tosti C, Andrei F, Biancone L, Palmieri G, Romeo F, Pallone F. Unsedated transnasal versus transoral sedated upper gastrointestinal endoscopy: a one-series prospective study on safety and patient acceptability. Digestive and Liver Disease 2008; 40(9): 767-775. doi: 10.1016/j.dld.2008.02.033; ISSN:1590-8658 (Impact Factor 4.088). 80. Biancone L, Sica GS, Calabrese E, Onali S, Patruzziello C, Pallone F. Frequency and pattern of endoscopic recurrence in Crohn's disease patients with ileocolonic resection using a laparoscopic versus laparotomic approach: a prospective longitudinal study (letter). American Journal of Gastroenterology 2008; 103(3): 809-811. doi:10.1111/j.1572-0241. 2007.01612_1 4.x 80. ISSN: 0002 9270 (Impact Factor 10.241). 81. Biancone L, Petruzziello C,Calabrese E, Zorzi F, Naccarato P, Onali S, Pallone F. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis? Gut 2009; 58(12): 1703. doi: 10.1136/gut.2008.176461. ISSN: 0017-5749 (Impact Factor 23.059). 82. Calabrese E, Petruzziello C, Onali S, Condino G, Zorzi F, Pallone F, Biancone L. Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. Inflammatory Bowel Diseases 2009; 15(11): 1635-1642. ISSN 1078-0998 doi: 10.1002/ibd.20948 (Impact Factor 5.325). 83. Onali S, Petruzziello C, Calabrese E, Condino G, Zorzi F, Sica GS, Pallone F, Biancone L. Frequency, pattern, and risk factors of postoperative recurrence of Crohn's disease after resection different from ileo-colonic. Journal of Gastrointestinal Surgery 2009; 13(2): 246-252. doi: 10.1007/s11605-008-0726-1. ISSN: 1091-255X (Impact Factor 3.452). 44/68 84. Onali S, Calabrese E, Petruzziello C, Zorzi F, Sica GS, Lolli E, Ascolani M, Condino G, Pallone F, Biancone L. Endoscopic vs ultrasonographic findings related to Crohn's disease recurrence: a prospective longitudinal study at 3 years. Journal of Crohn’s and Colitis 2010; 4(3): 319-328.ISSN:1873-9946; doi:10.1016/j.crohns. 2009.12.010 (Impact Factor 9.071). 85. Petruzziello C, Onali S, Calabrese E, Zorzi F, Ascolani M, Condino G, Lolli E, Naccarato P, Pallone F, Biancone L. Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease. World Journal of Gastroenterology 2010; 14;16(26): 3299-3304. doi: 10.3748/wjg.v16.i26.3299. ISSN: 1007-9327. (Impact Factor 5.742). 86. Onali S, Zorzi F, Calabrese E, Biancone L. Steroid-free remission and closure of recto-vaginal fistula using adalimumab in a Crohn's Disease patient naive to anti-tumor necrosis factor-alpha antibodies. Digestive and Liver Disease 2010; (Supplement) 4(1): 28-30. ISSN: 1594-5804. (Impact Factor 4.088). 87. Sica GS, Di Carlo S, Biancone L, Gentileschi P, Pallone F, Gaspari AL. Single access laparoscopic ileocecal resection in complicated Crohn's disease. Surgical Innovation 2010; 17(4): 359-360. doi: 10.1177/1553350610382014. ISSN: 1553-3506 (Impact Factor 2.058). 88. Petruzziello C, Calabrese E, Onali S, Zuzzi S, Condino G, Ascolani M, Zorzi F, Pallone F, Biancone L. Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's Disease. Journal of Crohn’s and Colitis 2011; 5(2): 139-147. doi: 10.1016/j.crohns.2010.12.004. ISSN:1873-9946 (Impact Factor 9.071). 89. Monteleone I, Rizzo A, Sarra M, Sica G, Sileri P, Biancone L, MacDonald T, Pallone F, Monteleone G. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 2011;41:237-248.doi:10.1053/j.gastro.2011.04.007, ISSN: 0016-5085 (Impact Factor 22.682). 90. Fina D, Franze’ E, Rovedatti L, Corazza GR, Biancone L, Sileri PP, Sica G, MacDonald TT, Pallone F, Di Sabatino A, Monteleone G. Interleukin-25 production is differently regulated by TNF-? and TGF-?1 in the human gut. Mucosal Immunology 2011:4(2):239-244.doi:10.1038/mi.2010.68.ISSN:1933-0219.(Impact Factor 6.33). 91. Sica GS, Iaculli E, Biancone L, Di Carlo S, Scaramuzzo R, Fiorani C, Gentileschi P, Gaspari AL. Comparative study of laparoscopic vs open gastrectomy in gastric cancer management. World Journal of Gastroenterology 2011:17:4602-4606. doi: 10.3748/wjg.v17.i41.4602. ISSN: 1007-9327 (Impact Factor 5.742). 45/68 92. Orlando A, Armuzzi A, Papi C, Annese V, Ardizzone S, Biancone L, Bortoli A, Castiglione F, D'Incà R, Gionchetti P, Kohn A, Poggioli G, Rizzello F, Vecchi M, Cottone M; Italian Society of Gastroenterology; Italian Group for the study of Inflammatory Bowel Disease. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease 2011: 43(1): 1-20. doi: 10.1016/j.dld.2010.07.010. ISSN: 1590-8658. (Impact Factor 4.088). 93. Morisco F. Castiglione F, Rispo A, Stroffolini T, Vitale R, Sansone S, Granata R, Orlando A, Marmo R, Riegler G, Vecchi M, Biancone L, Caporaso N. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Digestive and Liver Disease 2011; 43: Suppl 1:S40-48. doi: 10.1016/S1590-8658(10)60691-3. ISSN: 1590-8658 (Impact Factor 4.088). 94. Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Incà R, Zorzi F, Papi C, Meucci G, Riegler G, Sica G, Rizzello F, Mocciaro F, Onali S, Calabrese E, Cottone M, Pallone F. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflammatory Bowel Diseases 2011; 7;758-766.doi:10.1002/ibd.21416.ISSN 1078-0998 (Impact Factor 5.325). 95. Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, Danese S, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clinical Gastroenteroligy and Hepatology 2011; 9(1):30-5. doi: 10.1016/j.cgh.2010.09.026. ISSN 1542-3565 (Impact Factor 11.382). 96. Fiorani C, Scaramuzzo R, Lazzaro A, Biancone L, Palmieri G, Gaspari AL, Sica G. Intestinal duplication in adulthood: A rare entity, difficult to diagnose. World Journal of Gastrointestinal Surgery 2011;3(8):128-30. doi: 10.4240/wjgs.v3.i8.128; ISSN 1948-9366 (Impact Factor 2.582). 97. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group (Biancone L in the CERIFI Study Group). Ustekinumab induction and maintenance therapy in refractory Crohn's disease. The New England Journal of Medicine 2012; 367: 1519-1528. doi: 10.1056/NEJMoa1203572. ISSN 0028-4893 (Impact FActor 91.245). 98. Monteleone G, Fantini MC, Onali S, Zorzi F, Sancesario G, Bernardini S, Calabrese E, Viti F, Monteleone I, Biancone L, Pallone F. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Molecular Therapy 2012; 20: 870-876.doi:10.1038/mt.2011.290.ISSN:1525-0016 (Impact Factor 8.986) 46/68 99. Biancone L, Zuzzi S, Ranieri M, Petruzziello C, Calabrese E, Onali S, Ascolani M, Zorzi F, Condino G, Iacobelli S, Pallone F. Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. Journal of Crohn’s and Colitis 2012; 6: 578-587. doi: 10.1016/j.crohns.2011.11.005. CI 23 ISSN:1873-9946 (Impact Factor 9.071). 100. Onali S, Calabrese E, Petruzziello C, Zorzi F, Sica G, Fiori R, Ascolani M, Lolli E, Condino G, Palmieri G, Simonetti G, Pallone F, Biancone L. Small intestine contrast ultrasonography vs computed tomography enteroclysis for assessing ileal Crohn's disease. World Journal of Gastroenterology 2012; 18(42): 6088-6095.doi: 10.3748/wjg.v18.i42.6088. ISSN: 1007-9327 (Impact Factor 2.582). 101. Calabrese E, Zorzi F, Zuzzi S, Ooka S, Onali S, Petruzziello C, Lasinio GJ, Biancone L, Rossi C, Pallone F. Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn’s disease. Journal of Crohn’s and Colitis 2012; 6(8):852-860.doi:10.1016/j.crohns.2012.01.015.ISSN:1873-9946 (Impact Factor 9.071). 102. Zorzi F, Zuzzi S,Onali S, Calabrese E,Condino G,Petruzziello C,Ascolani M,Pallone F,Biancone L. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Alimentary Pharmacology & Therapeutics 2012;35(12):1397-1407.doi:10.1111/j.1365-2036.2012. 05100.ISSN:0269-2813 (Impact Factor 8.171). 103. Zorzi F, Calabrese E, Monteleone I, Fantini M, Onali S, Biancone L, Pallone F, Monteleone G. A phase 1 open-label trial shows that Smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease. Alimentary Pharmacology & Therapeutics 2012:36:850-857. doi:10.1016/j.crohns.2012.01.015; ISSN:0269-2813 (Impact Factor 8.171). 104. Calabrese E, Zorzi F, Onali S, Stasi E, Fiori R, Prencipe S, Bella A,Petruzziello C, Condino G, Lolli E, Simonetti G, Biancone L, Pallone F. Accuracy of Small Intestine Contrast Ultrasonography, compared to computed tomography enteroclysis, in characterizing lesions in patients with Crohn's Disease. Clinical Gastroenterology and Hepatology 2013:11:950-955. doi:10.1016/j.cgh.2013.01.015. ISSN 1542-3565 (Impact Factor 11.382). 105. Ciccacci C, Biancone L, Di Fusco D, Ranieri M, Condino G, Giardina E, Onali S, Lepre T, Pallone F, Novelli G, Borgiani. TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis 2013:7:44-53. doi:10.1016/j.crohns.2012.02.020. ISSN:1873-9946 (Impact Factor 9.071). 47/68 106. Calabrese E, Zorzi F, Visconti E, De Angelis G, Cerretti R, Del Vecchio Blanco G, Picardi A, Cudillo L, Postorino M, Franceschini L, Biancone L, Arcese W, Pallone F. Bowel ultrasonography as an aid for diagnosis of intestinal acute graft-versus-host-disease after allogeneic haematopoietic stem cell transplantation. Digestive and Liver Disease 2013; 45: 899-904. doi: 10.1016/j.dld.2013.04.004. ISSN: 1590-8658. (Impact Factor 4.088). 107. Cossu A, Biancone L, Ascolani M, Pallone F, Boirivant M. "In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-? production associate with drug response in patients with Crohn's Disease. Journal of Crohn’s and Colitis 2013: 7: 441-450. doi: 10.1016/j.crohns.2012.06.020. ISSN:1873-9946. (Impact Factor 9.071). 108. Manzia T, Sforza D, Biancone L, Tisone G. Liver abscess caused by foreign body ingestion. Digestive and Liver Disease 2013: 45(8): 699. doi: 10.1016/j.dld.2013.01.019 ISSN:1590-8658 (Impact Factor 4.088). 109. Zorzi F, Monteleone I, Sarra M, Calabrese E, Marafini I, Cretella M, Sedda S, Biancone L, Pallone F, Monteleone G. Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLoS One 2013; 8(1): E54562. doi: 10.1371/journal.pone.0054562; ISSN: 1932-6203 (IF 3.240). 110. Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, Danese S, Halligan S, Marincek B, Matos C, Peyrin-Biroulet L, Rimola J, Rogler G, van Assche G, Ardizzone S, Ba-Ssalamah A, Bali MA, Bellini D, Biancone L, Castiglione F, Ehehalt R, Grassi R, Kucharzik T, Maccioni F, Maconi G, Magro F, Martín-Comín J, Morana G, Pendsé D, Sebastian S, Signore A, Tolan D, Tielbeek JA, Weishaupt D, Wiarda B, Laghi A. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. Journal of Crohn’s and Colitis 2013; 7(7): 556-585. doi: 10.1016/j.crohns.2013.02.020.ISSN:1873-9946 (Impact Factor 9.071). 111. Sica GS, Biancone L. Surgery for inflammatory bowel disease in the era of laparoscopy. World Journal of Gastroenterology 2013; 19: 2445-2448. ISSN: 1007-9327; doi: 10.3748/wjg .v19.i16. 2445 (Impact Factor 2.582). 112. Franzè E, Caruso R, Stolfi C, Sarra M, Cupi ML, Caprioli F, Monteleone I, Zorzi F, De Nitto D, Colantoni A, Biancone L, Pallone F, Monteleone G. Lesional accumulation of CD163-expressing cells in the gut of patients with inflammatory bowel disease. PLoS One 2013: 8(7),e69839. ISSN: 1932-6203. doi: 10.1371/journal.pone.0069839 (IF 3.240). 113. Morisco F, Castiglione F, Rispo A, Stroffolini T, Sansone S, Vitale R, Guarino M, Biancone L, Caruso A, D'Inca R, Marmo R, Orlando A, Riegler G, Donnarumma L, Camera S, Zorzi F, Renna S, Bove V, Tontini G, Vecchi M, Caporaso N. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. Journal of Viral Hepatitis 2013; 20: 200-208. doi: 10.1111/j.1365-2893.2012.01643.x. ISSN: 1352-0504. (Impact Factor 3.728). 48/68 114. Del Vecchio Blanco G, Cretella M, Paoluzi AO, Mannisi E, Caruso A, Servadei, Giannelli M, Biancone L, Romeo S, Sileri P, Frasso E, Pallone F. Adenoma, advanced adenoma and colorectal cancer prevalence in asymptomatic 40- to 49-year-old subjects with a first-degree family history of colorectal cancer. Colorectal Disease 2013; 15: 1093-1099. doi: 10.1111/codi.12263. ISSN: 1462-8910 (Impact Factor 3.788). 115. Condino G, Calabrese E, Zorzi F, Onali S, Lolli E, De Biasio F, Ascolani M, Pallone F, Biancone L. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study. Digestive and Liver Disease 2013: 45: 258-262. doi: 0.1016/j.dld.2012.10.009. ISSN: 1590-8658. (Impact Factor 4.088). 116. Italian Group for the Study of Inflammatory Bowel Disease, Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, Aratari A, Ardizzone S, Balestrieri P, Bossa F, Cappello M, Castiglione F, Cicala M, Danese S, D'Incà R, Dulbecco P, Feliciangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, Kohn A, Lorenzetti R, Milla M, Onali S, Orlando A, Papparella LG, Renna S, Ricci C, Rizzello F, Sostegni R, Guidi L, Papi C. Adalimumab in active ulcerative colitis: a "real-life" observational study. Digestive and Liver Disease 2013; 45: 738-743. doi: 10.1016/j.dld.2013.03.018. ISSN: 1590-8658 (Impact Factor 4.088). 117. Orlando A, Mocciaro F, Renna S, Scimeca D, Rispo A, Lia Scribano M, Testa A, Aratari A, Bossa F, Tambasco R, Angelucci E, Onali S, Cappello M, Fries W, D'Incà R, Martinato M, Castiglione F, Papi C, Annese V, Gionchetti P, Rizzello F, Vernia P, Biancone L, Kohn A, Cottone M. Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) study on a large prospective multicenter cohort. Journal of Crohn’s and Colitis 2014;8(10):1217-21. doi:10.1016/j.crohns.2014.02.010. ISSN:1873-9946 (Impact Factor 9.071). 118. Annese V, Vecchi M, Italian Group for the Study of IBD (Biancone L, included in the Study Group). Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. Digestive and Liver Disease 2014; 46: 963-968. doi: 10.1016/j.dld.2014.07.019. ISSN: 1590-8658 (Impact Factor 4.088). 119. Di Domenicantonio R, Cappai G, Arcà M, Agabiti N, Kohn A, Vernia P, Biancone L, Armuzzi A, Papi C, Davoli M. Occurrence of inflammatory bowel disease in central Italy: A study based on health information systems. Digestive and Liver Disease 2014: 46: 777-782. doi: doi: 10.1016/j.dld.2014.04.014. ISSN: 1590-8658 (Impact Factor 4.088). 120. Daperno M, Comberlato, M, Bossa F, Biancone L, Bonanomi AG, Cassinotti A, Cosintino R, Lombardi G, Mangiarotti R, Papa A, Pica R, Rizzello F, D'Inca R, Orlando A. Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2014; 46: 969-973. doi: 10.1016/j.dld.2014.07.010- 10. ISSN: 1590-8658 (Impact Factor 4.088). 49/68 121. Zorzi F, Stasi E, Bevivino G, Scarozza P, Biancone L, Zuzzi S, Rossi C, Pallone F, Calabrese E. A Sonographic Lesion Index for Crohn's Disease helps monitor changes in transmural bowel damage during therapy. Clinical Gastroenterology and Hepatology 2014; doi: 10.1016/j.cgh.2014.04.036 31 2014. ISSN 1542 3565 (Impact Factor 11.382). 122. Sica GS, Di Carlo S, Tema G, Montagnese F, Del Vecchio Blanco G, Fiaschetti V, Maggi G, Biancone L. Treatment of peri-anal fistula in Crohn's disease. World Journal of Gastroenterology 2014; 20(37): 13205-13210. doi: 10.3748/wjg.v20.i37.13205. ISSN 1007-9327 (Impact Factor 5.742). 123. Biancone L, Calabrese E, Petruzziello C, Capanna A, Zorzi F, Onali S, Condino G, Lolli E, Ciccacci C, Borgiani P, Pallone F. A family study of asymptomatic small bowel Crohn's disease. Digestive and Liver Disease 2014: 46(3): 276-278. doi: 10.1016/j.dld.2013.11.003. ISSN: 1590-8658 (Impact Factor 4.088). 124. Monterubbianesi R, Aratari A, Armuzzi A, Daperno M, Biancone L, Cappello M, Annese V, Riegler G, Orlando A, Viscido A, Meucci G, Gasbarrini A, Guidi L, Lavagna A, Sostegni R, Onali S, Papi C, Kohn A; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. Journal of Crohn’s and Colitis 2014; 8(8): 852-8. doi:10.1016/j.crohns.2014.01.006. ISSN: 1873-9946. (Impact Factor 9.071). 125. Ascolani M, Mescoli C, Palmieri G, Sica G, Calabrese E, Petruzziello C, Onali S, Albertoni L, Lolli E, Condino G, Pallone F, Rugge M, Biancone L. Colonic phenotype of the ileum in Crohn's disease: a prospective study before and after ileocolonic resection. Inflammatory Bowel Diseases 2014: 20(9): 1555-1556. doi:10.1097/MIB.0000000000000127. ISSN 1078- 0998 (Impact Factor 5.325). 126. Fiorani C, Biancone L, Tema, G, Porokhnavets K, Tesauro M, Gaspari AL, Sica, GS. Laparoscopic ileocolic resection for Crohn's disease associated with midgut malrotation. Journal of the Society of Laparoscopic & Robotic Surgeons (SLS) 2014; Jul-Sep 18(3): e2014.11192. ISSN: 1086-8089, doi:10.4293/JSLS.2014.11192 (Impact Factor 1.462). 127. Caruso R, Marafini I, Franzè E, Stolfi C, Zorzi F, Monteleone I, Caprioli F, Colantoni A, Sarra M, Sedda S, Biancone L, Sileri P, Sica G, MacDonald T, Pallone F, Monteleone G. Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut. Mucosal Immunology 2014;7:1467-1479. ISSN: 1933-0219, doi: 10.1038/mi.2014.35 (IF 7.313). 128. Øresland T, Bemelman WA, Sampietro GM, Spinelli A, Windsor A, Ferrante M, Marteau P, Zmora O, Kotze PG, Espin-Basany E, Tiret E, Sica G, Panis Y, Faerden AE, Biancone L, Angriman I, Serclova Z, de Buck van Overstraeten A, Gionchetti P, Stassen L, Warusavitarne J, Adamina M, Dignass A, Eliakim R, Magro F, D'Hoore A; European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on surgery for ulcerative colitis. Journal of Crohn’s and Colitis 2015; 9(1): 4-25. doi: 10.1016/j.crohns.2014.08.012. ISSN 1873-9946 (IF 9.071). 50/68 129. D'Apice MR, Novelli A, di Masi A, Biancolella M, Antoccia A, Gullotta F, Licata N, Minella D, Testa B, Nardone AM, Palmieri G, Calabrese E, Biancone L, Tanzarella C, Frontali M, Sangiuolo F, Novelli G, Pallone F. Deletion of REXO1L1 locus in a patient with malabsorption syndrome, growth retardation, and dysmorphic features: a novel recognizable microdeletion syndrome? BMC Medical Genomics 2015; Apr 2: 16-20. doi: 10.1016/j.dld.2015.05.012. ISSN: 1471-2350. (Impact Factor IF 3.063). 130. Rufini S, Ciccacci C, Di Fusco D, Ruffa A, Pallone F, Novelli G, Biancone L, Borgiani P. Autophagy and inflammatory bowel disease: Association between variants of the autophagy-related IRGM gene and susceptibility to Crohn's disease. Digestive and Liver Disease 2015; 47: 744-750. doi: doi: 10.1016/j.dld.2015.05.012. ISSN: 1590-8658. (Impact Factor 4.088). 131. Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in IBD. Review. Inflammatory Bowel Diseases 2015; 21: 678-698. doi:10.1097/MIB.0000000000000243. ISSN 1078-0998. (Impact Factor 5.325). 132. Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R, European Crohn's Colitis Organization. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. Journal of Crohn’s and Colitis 2015; 9 (11): 945-965. doi: 10.1093/ecco-jcc/jjv141. ISSN 1873-9946. (Impact Factor 9.071). 133. Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando A, Pallone F. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. The New England Journal of Medicine 2015; 372(12) 1104-1113. doi: 10.1056/NEJMoa1407250-9. ISSN 0028-4893 (Impact Factor 91.245). 134. Lolli E, Saraceno R, Calabrese E, Ascolani M, Scarozza P, Chiricozzi A, Onali S, Petruzziello C, Chimenti S, Pallone F, Biancone L. Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study. Journal of Crohn’s and Colitis 2015; 9: 699-707. doi: 10.1093/ecco-jcc/jjv068. ISSN 1873-9946 (Impact Factor 9.071). 135. Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV Jr, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR. Risk of lymphoma in patients with Inflammatory Bowel Disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clinical Gastroenterology and Hepatology 2015: 13: 847-858; doi:10.1016/j.cgh.2014.05.015. ISSN 1542- 3565. (Impact Factor 11.382). 51/68 136. Biancone L, Armuzzi A, Scribano ML, D'Inca R, Castiglione F, Papi C, Angelucci E, Daperno M, Mocciaro F, Riegler G, Fries W, Meucci G, Alvisi P, Spina L, Ardizzone S, Petruzziello C, Ruffa A, Kohn A, Vecchi M, Guidi L, Di Mitri R, Renna S, Emma C, Rogai F, Rossi A, Orlando A, Pallone F; Italian Group for the study of Inflammatory Bowel Disease. inflammatory bowel disease phenotype as risk factor for cancer in a prospective multicentre nested case-control IG-IBD Study. Journal of Crohn’s and Colitis 2016: 10; 913-924; doi:10.1093/ecco-jcc/jjw048. ISSN 1873-9946 (Impact Factor 9.071). 137. Regueiro M, Feagan BG, Zou, Johanns, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie F, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P, PREVENT Study Group, Biancone L, included in the Study Group. Infliximab reduces endoscopic, but not clinical, recurrence of crohn's disease after ileocolonic resection. Gastroenterology 2016;150:1568-1578. doi: 10.1053/j.gastro.2016.02.072. ISSN: 0028-4793. (Impact Factor 22.682). 138. Iaculli E, Agostini M, Biancone L, Fiorani C, Di Vizia A, Montagnese F, Sibio S, Manzelli A, Tesauro M, Rufini A, Sica GS. C-reactive protein levels in the perioperative period as a predictive marker of endoscopic recurrence after ileo-colonic resection for Crohn's disease. Cell Death Discovery 2016; 2:16032. doi: 10.1038/cddiscovery.2016.32; ISSN 2058-7716. (Impact Factor 5.241). 139. Onali S, Calabrese E, Petruzziello C, Lolli E, Ascolani M, Ruffa A, Sica G, Rossi A, Chiaramonte C, Pallone F, Biancone L. Post-operative recurrence of Crohn's disease: A prospective study at 5 years. Digestive and Liver Disease 2016; 48: 489-494. doi: 10.1016/j. dld.2016.01.009. ISSN: 1590-8658. (Impact Factor 4.088). 140. Conigliaro P, Chimenti MS, Ascolani M, Triggianese P, Novelli L, Onali S, Lolli E, Calabrese E, Petruzziello C, Pallone F, Perricone R, Biancone L. Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. Autoimmunity Reviews 2016;15(2):184-190. doi: 10.1016/j.autrev.2015.11.002. ISSN: 1568-9972. (Impact Factor 9.754). Articolo originale. 141. Triggianese P, Conigliaro P, Chimenti MS, Biancone L, Monteleone G, Perricone R, Monteleone I. Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis. Clinical and Experimental Rheumatology 2016; 34: 1085-1093. doi:10.1016/j.dld.2017.01.161-8.ISSN: 0392-856X. (Impact Factor 2.980). 142. Vanoli A, Di Sabatino A, Martino M, Klersy C, Grillo F, Mescoli C, Nesi G, Volta U, Fornino D, Luinetti O, Fociani P, Villanacci V, D'Armiento FP, Cannizzaro R, Latella G, Ciacci C, Biancone L, Paulli M, Sessa F, Rugge M, Fiocca R, Corazza GR, Solcia E. Small bowel carcinomas in celiac or Crohn's disease: distinctive histophenotypic, molecular and histogenetic patterns. Modern Pathology 2017; 30: 1453-1466. doi: 10.1038/ modpathol. 2017.40. ISSN 0893-3952. (Impact Factor 7.842). 52/68 143. Biancone L, Albertoni L, Ascolani M, Mescoli C, Rugge M. Colonic metaplasia of the neo-terminal ileum in Crohn's Disease. Digestive and Liver Disease 2017; 49: 451. , doi: 10.1016/ j.dld 2016. 12.032. ISSN: 1590-8658 (Impact Factor 4.088). 144. Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017: 49: 338-358. doi: 10.1016/j.dld.2017.01.141. ISSN: 1590-8658 (Impact Factor 4.088). 145. Emerenziani S, Biancone L, Guarino MPL, Balestrieri P, Stasi E, Ribolsi M, Rescio MP, Altomare A, Cocca S, Pallone F, Cicala M. Nutritional status and bioelectrical phase angle assessment in adult Crohn’s disease patients receiving anti-TNF? therapy. Digestive and Liver Disease 2017; 49: 495-499. doi: DOI: 10.1016/j.dld.2016. ISSN: 1590-8658. (Impact Factor 4.088). 146. Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S, Italian Group for teh Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Digestive and Liver Disease 2017; 49(6): 604-617. doi: 10.1016/j.dld.2017.01.161. ISSN: 1590-8658. (Impact Factor 4.088). 147. Russo E, Lombardelli L, Giudici F, Cavalli T, Ficari F, Fazi M, Scaringi S, Biancone L, Logiodice F, Nesi M, Latiano A, Annese V, Torcia MG, Bechi P, Tonelli F, Piccinni MP, Marie-Pierre, Malentacchi C. Crohn's Colitis: Development of a multiplex gene expression assay comparing mRNA levels of susceptibility genes. Clinics and Research in Hepatology and Gastroenterology 2017; 41: 435-444. doi: 10.1016/j. clinre. 2017.02.004. ISSN: 2210-740. (Impact Factor 2.947). 148. Vanoli A, Di Sabatino A, Biancone L, Martino M, Macciomei MC, Zorzi F, Pallone F, Solcia E, Corazza GR. Small bowel Epstein-Barr virus-positive lympho-epithelioma-like carcinoma in Crohn's disease. Histopathology 2017;70: 837-:839. doi: 10.1007/s00428-017-2209-9. ISSN: 1365-2559. (Impact Factor 5.087). 149. Daperno M, Comberlato M, Bossa F, Armuzzi A, Biancone L, Bonanomi AG, Cosintino R, Lombardi G, Mangiarotti R, Papa A, Pica R, Grassano L, Pagana G, D'Incà R, Orlando A, Rizzello F, IGIBDEndo Group. Training programs on endoscopic scoring systems for Inflammatory Bowel Disease in interobserver agreement among community gastroenterologists. Journal of Crohn’s and Colitis 2017;11:556-561.doi:10.1093/ecco-jcc/jjw181; ISSN 1873-9946 (IF 9.071). 53/68 150. Ciccacci C, Politi C, Biancone L, Latini A, Novelli G, Calabrese E, Borgiani P. Polymorphisms in MIR122, MIR196A2, and MIR124A Genes are associated with clinical phenotypes in Inflammatory Bowel Diseases. Molecular Diagnosis & Therapy 2017; 21:107-114. doi:10.1007/s40291-016-0240-1;ISSN: 1177-1062. 151. Vanoli A, Sabatino AD, Furlan D, Klersy C, Grillo F, Fiocca R, Mescoli C, Rugge M, Nesi G, Fociani P, Sampietro G, Ardizzone S, Luinetti O, Calabrò A, Tonelli F, Volta U, Santini D, Caio G, GiuffridaP, Elli L, Ferrero S, Latella G, Ciardi A, Caronna R, Solina G, Rizzo A, Ciacci C, D'Armiento FP, Salemme M, Villanacci V, Cannizzaro R, Canzonieri V, Reggiani Bonetti L, Biancone L, Monteleone G, Orlandi A, Santeusanio G, Macciomei MC, D'Incà R, Perfetti V, Sandri G, Silano M, Florena AM, Giannone AG, Papi C, Coppola L, Usai P, Maccioni A, Astegiano M, Migliora P, Manca R, Martino M, Trapani D, Cerutti R, Alberizzi P, Riboni R, Sessa F, Paulli M, Solcia E, Corazza GR. Small bowel carcinomas in Coeliac or Crohn’s Disease: clinico-pathological, molecular and prognostic features. a study from the Small Bowel Cancer Italian Consortium. Journal of Crohn’s and Colitis 2017;11: 942-953. doi: 10.1093/ecco-jcc/jjx031. ISSN 1873-9946. (Impact Factor 9.071). 152. Messina V, Buccione C, Marotta G, Ziccheddu G, Signore M, Mattia G, Puglisi R, Sacchetti B, Biancone L, Valtieri M. Gut mesenchymal stromal cells in immunity. Stem Cells International 2017:8482326. doi: 10.1155/2017/8482326..ISSN 2005-3606. (Impact Factor 5.443). 153. Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, Bossa F, Maconi G, D?Incà R, Lionetti P, Cantoro L, Fries W, Annunziata ML, Costa F, Terpin MM, Biancone L, Cortelezzi CC, Amato A, Ardizzone S, Danese S, Guidi L, Rizzuto G, Massella A, Andriulli A, Massari A, Lorenzon G, Ghione S, Kohn A, Ventra A, Annese V; PROSIT-BIO Cohort. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflammatory Bowel Diseases 2017; 23(2): 233-243. doi: 10.1097/MIB.0000000000000995. ISSN 1078-0998. (Impact Factor 5.325). 154. Armuzzi A, Felice C, Lubrano E, Cantinic F, Castiglione F, Gionchetti P, Orlando A, Salvarani 150.C, Scarpa R, Marchesoni A, Vecchi M, Olivieri I, on behalf of the Italian SpA-IBD Expert Panel Group (*Including Biancone L, vedi fine articolo e PubMed). Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. Consensus Digestive and Liver Disease 2017; 49;1298-1305. ISSN: 1590-8658.(Impact Factor 4.088). 155. Vanoli A, Di Sabatino A, Martino M, Dallera E, Furlan D, Mescoli C, Macciomei MC, Biancone L, Neri B, Grillo F, Biletta E, Rugge M, Sessa F, Paulli M, Corazza GR, Solcia E. Epstein-Barr virus-positive ileal carcinomas associated with Crohn's disease. Virchows Arch 2017; 471(4):549-552. doi: 10.1007/s00428-017-2209-9.ISSN 0945-6317 (IF 4.064). 156. Armuzzi A, Ardizzone S, Biancone L, Castiglione F, Danese S, Gionchetti P, Orlando A, Rizzello F, Scribano ML, Vecchi M, Daperno M. Ustekinumab in the management of Crohn's disease: expert opinion. Digestive and Liver Disease 2018; 50(7): 653-660. Review. doi: 10.1016/j.dld.2018.02.017.ISSN: 1590-8658. (Impact Factor 4.088). 54/68 157. Sibio S, Di Giorgio A, Campanelli M, Di Carlo S, Divizia A, Fiorani C, Scaramuzzo R, Arcudi C, Del Vecchio Blanco G, Biancone L, Sica G. Ambulatory surgery for perianal Crohn's Disease: study of feasibility. Gastroenterology Research and Practice 2018; 5249087. doi: 10.1155/2018/5249087. ISSN 1687-6121 (Impact Factor 2.260) 158. Bemelman WA, Warusavitarne J,Sampietro GM, Serclova Z, Luglio G,, van Overstraeten, AB,Burke JP,Buskens CJ,Colombo F,Dias JA,Eliakim R,Elosua, T,Gecim IE,Kolacek S,Kierkus J,Kolho K.-L.Lefevre JM, Millan M,Panis Y, Pinkney, T,Russell RK,Shwaartz C,Vaizey C,Yassin N,D'Hoore, A,Högenauer, C,Bogut, A,Mijandrusic-Sincic B,Kaimakliotis, I,Jorn B,Kull K,Bourreille A,Siegmund B,Koutroubakis I,Lakatos, P,Kohn A,Turcan S,Zagorowicz E,Diculescu MM,Pierik M,Kotze PG,Hojsak, I,Brüwer M, Biancone L, Scaringi S,Sica G,Gasparetto M,Dardanov D,Omar W,Lepistö A,Stefansson T,Wasserberg N,Lorenc Z,Kosorok, P,Buchwald, P,Bugra D,Nugent K,Kronberger IE,El-Hussuna, A,Kienle, P,Ruffolo C,Basany EE,Myrelid, P,Kvasnovsky C ,on behalf of the European Crohn's and Colitis Organisation. ECCO-ESCP consensus on surgery for Crohn's disease. Journal of Crohn’s and Colitis 2018; 12(1): 1-16. ISSN 1873-9946 (Impact Factor 9.071). 159. Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D'Incà R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni S, Amato A, Ardizzone S, Guidi L, Danese S, Massella A, Ventra A, Rizzuto G, Massari A, Perri F, Annese V; PROSIT Investigators. Tthe PROSIT cohort of Infliximab biosimilar in ibd: a prolonged follow-up on the effectiveness and safety across Italy. Inflammatory Bowel Diseases 2019; 25(3): 568-579. doi: 10.1093/ibd/izy264. ISSN 1078-0998. (Impact Factor 5.325). 160. Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A; National patients’ association representatives (Including Biancone L). Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2019; 51(5): 632-639. doi: 10.1016/j.dld.2019.02.004.:1590-8658; ISSN 1590-8658. (Impact Factor 4.088). 161. Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, Orlando A, Viola A, Fries W, Rispo A, Castiglione F, Mocci G, Chicco F, Usai P, Calabrese E, Biancone L, Monteleone G, Fantini MC; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Comparative efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis patients previously treated with Infliximab. Inflammatory Bowel Diseases 2019; 25(11): 1805-1812. doi: 10.1093/ibd/izz057. ISSN 1078-0998. (Impact Factor 5.325). 162. Chimenti MS, Conigliaro P, Triggianese P, Canofari C, Cedola F, Onali S, Calabrese E, Romeo S, Neri B, De Cristofaro E, Biancone L, Perricone R. Use of synthetic and biological DMARDs in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological approach. Clinical and Experimental Rheumatology 2019; 37(5): 723-730. ISSN 0392-856X. (Impact Factor 4.473). 55/68 163. Lo Presti A, Zorzi F, Del Chierico F, Altomare A, Cocca S, Avola A, De Biasio F, Russo A, Cella E, Reddel S, Calabrese E, Biancone L, Monteleone G, Cicala M, Angeletti S, Ciccozzi M, Putignani L, Guarino MPL. Fecal and mucosal microbiota profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease. Frontiers in Microbiology 2019; 10: 1655. doi: 10.3389/fmicb.2019.01655. ISSN 1664-302X. (Impact Factor 22.378). 164. Giudici F, Lombardelli L, Russo E, Cavalli T, Zambonin D, Logiodice F, Kullolli O, Giusti L, Bargellini T, Fazi M, Biancone L, Scaringi S, Clemente AM, Perissi E, Delfino G, Torcia MG, Ficari F, Tonelli F, Piccinni MP, Malentacchi C. Multiplex gene expression profile in inflamed mucosa of patients with Crohn's disease ileal localization: A pilot study. World Journal of Clinical Cases 2019; 7(17): 2463-2476. doi: 10.12998/wjcc.v7.i17.2463. ISSN 2307-8960. (Impact Factor 1.337). 165. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group (Biancone L inclusa nell’ UNIFI Study Group, vedi articolo e PubMed). Ustekinumab as induction and maintenance therapy for Ulcerative Colitis. The New England Journal of Medicine 2019; 381(13): 1201-1214. doi: 10.1056/NEJMoa1900750. ISSN 0028-4893 (Impact Factor 91.245). 166. Chimenti MS, Conigliaro P, Triggianese P, Canofari C, Cedola F, Onali S, Calabrese E, Romeo S, Neri B, De Cristofaro E, Biancone L, Perricone R. Use of synthetic and biological DMARDs in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological approach. Clinical and Experimental Rheumatology 2019; 37(5): 723-730. ISSN 0392-856X. (Impact Factor 4.473) 167. Pugliese D, Daperno M, Fiorino G, Savarino E, Mosso E, Biancone L, Testa A, Sarpi L, Cappello M, Bodini G, Caprioli F, Festa S, Laino G, Maconi G, Mazzuoli S, Mocci G, Sartini A, D'Amore A, Alivernini S, Gremese E, Armuzzi A. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Digestive and Liver Disease 2019; 51(7): 972-977. doi: 10.1016/j.dld.2019.03.007. ISSN: 1590-865 (Impact Factor 4.088). 168. Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, Orlando A, Viola A, Fries W, Rispo A, Castiglione F, Mocci G, Chicco F, Usai P, Calabrese E, Biancone L, Monteleone G, Fantini MC; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Comparative efficacy of vedolizumab and adalimumab in ulcerative colitis patients previously treated with Infliximab. Inflammatory Bowel Diseases 2019; 25(11):1805-1812.doi 10.1093/ibd/izz057; ISSN 1078-0998. (IF 5.325). 169. Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A; National patients’ association representatives (including Biancone L, vedi articolo e PubMed). Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive Liver Disease 2019;51(5): 632-639.Review.doi:10.1016/j.dld.2019.02.004.ISSN:1590-8658 (IF 4.088) 56/68 170. Franzè E, Di Grazia A, Sica GS, Biancone L, Laudisi F, Monteleone G. Interleukin-34 Enhances the tumor promoting function of colorectal cancer-associated fibroblasts. Cancers 2020;12(12):3537. doi: 10.3390/cancers12123537. ISSN: 2072-6694. (Impact Factor 6.639). 171. Biancone L, Armuzzi A, Scribano ML, Castiglione F, D'Incà R, Orlando A, Papi C, Daperno M, Vecchi M, Riegler G, Fries W, Alvisi P, Meucci G, Mocciaro F, Rogai F, Festa S, Guidi L, Testa A, Spina L, Renna S, Viola A, Patturelli M, Di Mitri R, Frankovic I, Calabrese E, Petruzziello C, De Cristofaro E, Sena G, Ruffa A, Neri B, Rossi A. Cancer risk in Inflammatory Bowel Disease: A 6-year prospective multicenter nested case-control IG-IBD study. Inflammatory Bowel Diseases 2020; 26(3): 450-459. doi: 10.1093/ibd/izz155. ISSN 1078-0998 (Impact Factor 5.325). 172. Zorzi F, Ghosh S, Chiaramonte C, Lolli E, Ventura M, Onali S, De Cristofaro E, Fantini MC, Biancone L, Monteleone G, Calabrese E. Response assessed by ultrasonography as target of biological treatment for Crohn's Disease. Clinical Gastroenterology & Hepatology 2020; 18(9): 2030-2037. doi: 10.1016/j.cgh.2019.10.042. ISSN 1542-356 (Impact Factor 11.382). 173. Orlando A, Mocciaro F, Ventimiglia M, Renna S, Rispo A, Scribano ML, Testa A, Aratari A, Bossa F, Angelucci E, Onali S, Cappello M, Giunta M, Scimeca D, Macaluso FS, Castiglione F, Papi C, Annese V, Biancone L, Kohn A, Di Mitri R, Cottone M. Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial. European Review for Medical and Pharmacological Sciences 2020; 24(21):11356-11364. doi: 10.26355/ eurrev_202011_23627. ISSN: 1128-3602 (Impact Factor 3.507). 174. Chimenti MS, Conigliaro P, Polistena B, Triggianese P, D'Antonio A, Neri B, Sena G, Spandonaro F, Biancone L, Perricone R. Observational study on the evaluation of quality of life in patients affected by enteropathic spondyloarthritis. Musculoskeletal Care 2020; 18(4): 527-534. doi: 10.1002/msc.1500. ISSN 1557-0681 (Impact Factor 1.277). 175. Scucchi L, Neri B, Argirò R, Nasso D, Provenzano I, Potenza S, Mossa M, Di Prete M, Calabrese E, Petruzziello C, Mauriello A, Monteleone G, Cantonetti M, Biancone L. Hepatic follicular lymphoma in an old patient with Crohn's disease: a rare case and review of the literature. European Review for Medical and Pharmacological Sciences 2020;24(19):10045-10050. doi: 10.26355/ eurrev_202010_23219. ISSN: 1128- 3602 (Impact Factor 3.507). 176. Zorzi F, Calabrese E, Di Fusco D, De Cristofaro E, Biancone L, Casella S, Palmieri G, Monteleone G. High Smad7 in the early post-operative recurrence of Crohn's disease. Journal of Translational Medicine 2020; 18 (1): 395. doi: 10.1186/s12967-020-02558-8. ISSN: 1479 5876. (Impact Factor 5.531) 57/68 177. Fantini MC, Biancone L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Guglielmi FW, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Di Ruscio M, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Saibeni S, Fiorino G. telemedicine and remote screening for covid-19 in inflammatory bowel disease patients: results from the SoCOVID-19 Survey. Inflammatory Bowel Diseases 2020; 26(11): e134-e136. doi: 10.1093/ibd/izaa254. ISSN 1078-0998. (Impact Factor 5.325). 178. Biancone L, Ardizzone S, Armuzzi A, Castiglione F, D'Incà R, Danese S, Daperno M, Gionchetti P, Rizzello F, Scribano ML, Vecchi M, Orlando A. Ustekinumab for treating ulcerative colitis: an expert opinion. Expert Opinion on Biological Therapy 2020; 20 (11): 1321-1329. Review; doi: 10.1080/14712598.2020. 1792882. ISSN 1471-2598 (Impact Factor 4.388). 179. Scarozza P, De Cristofaro E, Scucchi L, Rocchetti I, Marafini I, Neri B, Salvatori S, Biancone L, Calabrese E, Monteleone G. effect of vedolizumab on anemia of chronic disease in patients with Inflammatory Bowel Diseases. Journal of Clinical Medicine 2020; 9 (7): 2126. doi: 10.3390/jcm9072126. ISSN: 2077-0383. (Impact Factor 4.241). 180. Marafini I, Salvatori S, Sena G, Calabrese E, Biancone L, Monteleone G. Low frequency of COVID-19 in inflammatory bowel diseases. Digestive and Liver Disease 2020; 52(11): 1234-1235. doi: 10.1016/j.dld.2020.06.007. ISSN:1590-8658. (Impact Factor 4.088). 181. Del Vecchio Blanco G, Calabrese E, Biancone L, Monteleone G, Paoluzi OA The impact of COVID-19 pandemic in the colorectal cancer prevention. International Journal of Colorectal Disease 2020; 35(10): 1951-1954. doi: 10.1007/s00384-020-03635-6. ISSN 0179-1958 (Impact Factor 2.571). 182. Sica GS, Di Carlo S, D'Ugo S, Arcudi C, Siragusa L, Fazzolari L, Biancone L, Monteleone G, Cardi M, Sibio S. Minimal open access ileocolic resection in complicated Crohn's Disease of the terminal ileum. Gastroenterology Research and Practice 2020 feb 28: 6019435. doi: 10.1155/2020/6019435; ISSN 1687-6121 (Impact Factor 2.260). 183. D'Ugo S, Romano F, Sibio S, Bagaglini G, Sensi B, Biancone L, Monteleone G, Sica GS. Impact of surgery on quality of life in Crohn's disease: short- and mid-term follow-up. Updates in Surgery 2020; 72(3): 773-780. doi: 10.1007/s13304-020-00738-1. ISSN 2038-3312 (Impact Factor 2.797). 58/68 184. Giuffrida P, Arpa G, Grillo F, Klersy C, Sampietro G, Ardizzone S, Fociani P, Fiocca R, Latella G, Sessa F, D'Errico A, Malvi D, Mescoli C, Rugge M, Nesi G, Ferrero S, Furlan D, Poggioli G, Rizzello F, Macciomei MC, Santini D, Volta U, De Giorgio R, Caio G, Calabrò A, Ciacci C, D'Armiento M, Rizzo A, Solina G, Martino M, Tonelli F, Villanacci V, Cannizzaro R, Canzonieri V, Florena AM, Biancone L, Monteleone G, Caronna R, Ciardi A, Elli L, Caprioli F, Vecchi M, D'Incà R, Zingone F, D'Odorico A, Lenti MV, Oreggia B, Reggiani Bonetti L, Astegiano M, Biletta E, Cantoro L, Giannone AG, Orlandi A, Papi C, Perfetti V, Quaquarini E, Sandri G, Silano M, Usai P, Barresi V, Ciccocioppo R, Luinetti O, Pedrazzoli P, Pietrabissa A, Viglio A, Paulli M, Corazza GR, Solcia E, Vanoli A, Di Sabatino A. PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability. Modern Pathology 2020; 33(7): 1398-1409. doi: 10.1038/s41379-020-0497-0. ISSN 0893-3952 (Impact Factor 7.842). 185. Neri B, Stingone C, Romeo S, Sena G, Gesuale C, Compagno M, De Cristofaro E, Baciorri F, Del Vecchio Blanco G, Palmieri G, Sarmati L, Biancone L. Inflammatory bowel disease versus Chlamydia trachomatis infection: a case report and revision of the literature. European Journal of Gastroenterology & Hepatoogy 2020; 32(3): 454-457. doi:10.1097/ MEG.0000000 0 00001605. ISSN: 0954-691X (Impact Factor 2.566). 186. Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, Doherty G, El-Hussuna A, Ellul P, Fiorino G, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gisbert JP, Gomollon F, González Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Kucharzik T, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Stassen L, Torres J, Uzzan M, Vavricka S, Verstockt B, Zmora O. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. Journal of Crohn’s and Colitis 2020;14(2):155-168. doi:10.1093/ecco-jcc/jjz187. ISSN 1873-9946. (Impact Factor 9.071). 187. Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on therapeutics in Crohn's Disease: medical treatment. Journal of Crohn’s and Colitis 2020; 14(1): 4-22. doi: 10.1093/ecco-jcc/jjz180. ISSN 1873-9946. (Impact Factor 9.071). 188. Arpa G, Grillo F, Giuffrida P, Nesi G, Klersy C, Mescoli C, Lenti MV, Lobascio G, Martino M, Latella G, Malvi D, Macciomei MC, Fociani P, Villanacci V, Rizzo A, Ferrero S, Sessa F, Orlandi A, Monteleone G, Biancone L, Cantoro L, Tonelli F, Ciardi A, Poggioli G, Rizzello F, Ardizzone S, Sampietro G, Solina G, Oreggia B, Papi C, D'Incà R, Vecchi M, Caprioli F, Caronna R, D'Errico A, Fiocca R, Rugge M, Corazza GR, Luinetti O, Paulli M, Solcia E, Di Sabatino A, Vanoli A. Separation of Low- Versus High-grade Crohn's Disease-associated small bowel carcinomas is Improved by invasive front prognostic marker analysis. Journal of Crohn’s and Colitis 2020; 14(3): 295-302. doi: 10.1093/ecco-jcc/jjz140. ISSN 1873-9946 (Impact Factor 9.071 59/68 189. Marafini I, Salvatori S, Rocchetti I, Alfieri N, Scarozza P, Calabrese E, Biancone L, Monteleone G. Natural History of Ulcerative Colitis with coexistent colonic diverticulosis. Journal of Clinical Medicine 2021;10(6):1192. doi: 10.3390/jcm10061192. ISSN: 2077-0383 (Impact Factor 4.241). 190. Conigliaro P, Chimenti MS, Triggianese P, D'Antonio A,Sena G,Alfieri N, Biancone L, Perricone R. Two years follow-up of golimumab treatment in refractory enteropathic spondyloarthritis patients with Crohn disease: A STROBE-compliant study. Medicine (Baltimore) 2021; 100(12): e25122; doi: 10.1097/MD.0000000000025122; ISSN: 0025-7974. (Impact Factor 1.889). 191. Scucchi L, Neri B, Sarmati L, Mossa M, Sena G, Massoud R, Petruzziello C, Musumeci M, Marafini I, Calabrese E, Lolli E, Bernardini S, Andreoni M, Monteleone G, Biancone L. Low prevalence of SARS-CoV-2 infection in Inflammatory Bowel Disease. European Review for Medical and Pharmacological Sciences 2021;25(5): 2418 2424. doi:10.26355/ eurrev _202103_25283;ISSN:128-3602 (Impact Factor 3.507). 192. Chimenti MS, Conigliaro P, Biancone L, Perricone R. Update on the therapeutic management of patients with either psoriatic arthritis or Ulcerative Colitis: focus on the JAK inhibitor tofacitinib. Review. Theapeutic Advances in Musculoskeletal Disease 2021;13:doi:1759720X20977777; ISSN 1759-720X. (Impact Factor 5.346). 193. Neri B, Mossa M, Scucchi L, Sena G, Palmieri G, Biancone L. Histological scores in Inflammatory Bowel Disease. Review. Journal of Digestive Diseases 2021;22(1):9-22. doi: 10.1111/1751-2980.12937. ISSN 1751-2980. (Impact Factor 2.325). 194. Neri B, Scarozza P, Giannarelli D, Sena G, Mossa M, Lolli E, Calabrese E, Biancone L, Grasso E, Di Iorio L, Troncone E, Monteleone G, Paoluzi OA, Del Vecchio Blanco G Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2021 Jul 1;33(7):977-982. doi: 10.1097/MEG. 0000000000002167.PMID: 34034275 195. Vanoli A, Grillo F, Guerini C, Neri G, Arpa G, Klersy C, Nesi G, Giuffrida P, Sampietro G, Ardizzone S, Fociani P, Fiocca R, Latella G, Sessa F, D'Errico A, Malvi D, Mescoli C, Rugge M, Ferrero S, Poggioli G, Rizzello F, Macciomei MC, Santini D, Volta U, De Giorgio R, Caio G, Calabrò A, Ciacci C, D'Armiento M, Rizzo A, Solina G, Martino M, Tonelli F, Villanacci V, Cannizzaro R, Canzonieri V, Florena AM, Biancone L, Monteleone G, Caronna R, Ciardi A, Elli L, Caprioli F, Vecchi M, D'Incà R, Zingone F, D'Odorico A, Lenti MV, Oreggia B, Reggiani Bonetti L, Giannone AG, Orlandi A, Barresi V, Ciccocioppo R, Amodeo G, Biletta E, Luinetti O, Pedrazzoli P, Pietrabissa A, Corazza GR, Solcia E, Paulli M, Di Sabatino A. Prognostic role of mismatch repair status, histotype and high-risk pathologic features in stage ii small bowel adenocarcinomas. Annals of Surgical Oncology 2021; 28(2): 1167-1177. doi: 10.1245/s10434-020-08926-4. ISSN 1068-9265. (Impact Factor 5.344). 60/68 196. Benfaremo D, Luchetti MM, Di Carlo M, Laganà B, Picchianti-Diamanti A, Carubbi F, Pica R, Chimenti MS, Lorenzetti R, Scolieri P, Bruzzese V, Benedetti A, Ramonda R, Giacomelli R, Salaffi F, Gabrielli, Biancone L inclusa nel GRADES-IBD Study Group, Including Biancone L, see PubMed). Multicenter validation of the DETAIL questionnaire for the screening of spondyloarthritis in patients with Inflammatory Bowel Diseases. GRADES-IBD Study Group. The Journal of Rheumatology 2021; 48(2): 179-187. doi: 10.3899/jrheum.200364. ISSN 0315-162X (Impact Factor 2.519) 197. Marafini I, Stolfi C, Troncone E, Lolli E, Onali S, Paoluzi OA, Fantini MC, Biancone L, Calabrese E, Di Grazia A, Monteleone I, Lenti MV, Di Sabatino A, Monteleone G. A pharmacological batch of Mongersen that downregulates SMAD7 is effective as induction therapy in active Crohn's Disease: A Phase II, Open-Label Study. BioDrugs 2021; 35(3): 325-336. doi: 10.1007/s40259-021-00482-x; ISSN 1179-190X (Impact Factor 5.807). 198. Romeo S,Neri B, Mossa M, Calabrese E, Lolli E, Sena G, Gesuale C, Chiaramonte C, Biancone L. Finger clubbing in inflammatory bowel disease: association with upper small bowel lesions and need of surgery in Crohn's disease. European Journal of Gastroenterology & Hepatoogy 2021; 33(6): 844-851. doi: 10.1097/MEG.000000 0000001966; ISSN:0954-691X (Impact Factor 2.566). 199.Neri B, Scarozza P, Giannarelli D, Sena G, Mossa M, Lolli E, Calabrese E, Biancone L, Grasso E, Di Iorio L, Troncone E, Monteleone G, Paoluzi OA, Del Vecchio Blanco G. Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases. European Journal of Gastroenterology & Hepatoogy 2021; 33(7):977-982. doi: 10.1097/MEG.00000000 00002167. ISSN: 0954-691X (Impact Factor 2.566). 200. Romeo S, Neri B, Mossa M, Riccioni ME, Scucchi L, Sena G, Potenza S, Petruzziello C, Biancone L. Diagnostic yield of small bowel capsule endoscopy in obscure gastrointestinal bleeding: a real-world prospective study. Internal and Emergency Medicine 2022 Mar;17(2):349-358. doi: 10.1007/s11739-021-02791-z. Epub 2021 Jun 27.PMID: 34176039 201. Vanoli A, Guerini C, Klersy C, Fassan M, Arpa G, Neri G, Luinetti O, Lenti MV, Ulivi P, Tedaldi G, Furlan D, Quaquarini E, Ardizzone Sm Sampietro G, Biancone L, Monteleone G, Solcia E, Sessa F, Paulli M, Adsay NV, Di Sabatino A. Poorly cohesive carcinoma of the nonampullary small Intestine: A distinct histologic subtype with prognostic significance. The American Journal of Surgical Pathology 2021; Oct 11. doi: 10.1097/PAS.0000000 000001821. Online ahead of print (Impact Factor 6.394). 61/68 202. Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)(including Biancone L, see PubMed). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Alimentary Pharmacology and Therapeutics .2021; Dec 54 (11-12): 1432-1441. doi: 10.1111/apt. 16663 (Impact Factor 8.171). 203. De Cristofaro E, Salvatori S, Marafini I, Zorzi F, Alfieri N, Musumeci M,Biancone L, Calabrese E, Monteleone G.J Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids. Journal of Clinical Medicine 2021 Nov 19;10(22):5413. doi: 10.3390/jcm10225413.PMI; ISSN: 2077-0383 (Impact Factor 4.241). 204. Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1432-1441. doi: 10.1111/apt.16663. Epub 2021 Oct 25.PMID: 34694009 205. Danese S, Colombel JF, Gisbert P, D’Haens G, Hayee B, Panaccione R, Kim HS, Reinish W, Tyrren H, Oh YS, Tole S, Chai A, Chamberklain Janes Km Schreiber S, GARDENIA Study Group (Biancone L included in the Study Group, see PubMed). Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17.PMID: 34798038 Clinical Trial (Impact Factor 18.486). 206. Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group (Biancone L included in the Study Group, see PubMed). Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17.PMID: 34798039 (Impact Factor 18.486). 207. Scucchi L, Neri B, Sarmati L, Mossa M, Sena G, Massoud R, Petruzziello C, Musumeci M, Marafini I, Calabrese E, Lolli E, Bernardini S, Andreoni M, Monteleone G, Biancone L Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease..Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2418-2424. doi:10.26355/eurrev_202103_25283.PMID: 33755981 62/68 208. Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Sulais EA, Axelrad JE, Balendran K, Burisch J, de Ridder L, Derikx L, Ellul P, Greuter T, Iacucci M, Di Jiang C, Kapizioni C, Karmiris K, Kirchgesner J, Laharie D, Lobatón Ortega T, Molnár T, Noor NM, Rao R, Saibeni S, Scharl M, Vavricka SR, Raine T ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. .J Crohns Colitis. 2022 Dec 18:jjac187. doi: 10.1093/ecco-jcc/jjac187. Online ahead of print.PMID: 36528797 209. Salvatori S, Marafini I, Venuto C, Laudisi F, Neri B, Lavigna D, Franchin M, De Cristofaro E, Biancone L, Calabrese E, Giannarelli D, Monteleone G Frail Phenotype in Patients With Inflammatory Bowel Disease. .Inflamm Bowel Dis. 2022 Dec 2:izac242. doi: 10.1093/ibd/izac242. Online ahead of print.PMID: 36458964 210. Lolli E, De Cristofaro E, Marafini I, Troncone E, Neri B, Zorzi F, Biancone L, Calabrese E, Monteleone G Endoscopic Predictors of Neoplastic Lesions in Inflammatory Bowel Diseases Patients Undergoing Chromoendoscopy. Cancers (Basel). 2022 Sep 12;14(18):4426. doi: 10.3390/cancers14184426.PMID: 36139586 211. Mossa M, Neri B, Montesano L, Salvatori S, Marafini I, Scucchi L, Lolli E, Massoud R, Petruzziello C, Bernardini S, Calabrese E, Monteleone G, Biancone L SARS-CoV-2 Igg seroprevalence in IBD patients treated with biologics: first vs. second pandemic wave in a prospective study. Eur Rev Med Pharmacol Sci. 2022 May;26(10):3787-3796. doi: 10.26355/eurrev_ 202205_28875.PMID: 35647861. 212. Onali S, Pugliese D, Caprioli FA, Orlando A, Biancone L, Nardone OM, Imperatore N, Fiorino G, Cappello M, Viola A, Principi MB, Bezzio C, Aratari A, Carparelli S, Mazzuoli S, Manguso F, Grossi L, Bodini G, Ribaldone D, Mocci G, Miranda A, Minerba L, Favale A, Grova M, Scucchi L, Segato S, Fries W, Castiglione F, Armuzzi A, Fantini MC; IG-IBD. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors. Am J Gastroenterol. 2022 Aug 1;117(8):1279-1287. doi: 10.14309/ajg.0000000000001773. Epub 2022 Apr 13.PMID: 35467558. 213. Chaparro M, Kunovský L, Aguas M, Livne M, Rivière P, Bar-Gil Shitrit A, Myrelid P, Arroyo M, Barreiro-de Acosta M, Bautista M, Biancone L, Biron IA, Boysen T, Carpio D, Castro B, Dragoni G, Ellul P, Holubar SD, de Jorge MÁ, Leo E, Manceñido N, Moens A, Molnár T, Ramírez de la Piscina P, Ricanek P, Sebkova L, Sempere L, Teich N, Gisbert JP, Julsgaard M Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]. J Crohns Colitis. 2022 Sep 8;16(9):1428-1435. doi: 10.1093/ecco-jcc/jjac050.PMID: 35380641 214. Scribano ML, Aratari A, Neri B, Bezzio C, Balestrieri P, Baccolini V, Falasco G, Camastra C, Pantanella P, Monterubbianesi R, Tullio A, Saibeni S, Papi C, Biancone L, Cosintino R, Faggiani R Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy. Therap Adv Gastroenterol. 2022 Feb 14;15:17562848211072412. doi: 10.1177/ 17 562848211072412. eCollection 2022.PMID: 35186121 63/68 215. Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Dig Liver Dis. 2022 Apr;54(4):440-451. doi: 10.1016/j.dld.2022.01.127. Epub 2022 Feb 17.PMID: 35184989 216. Neri B, Scribano ML, Armuzzi A, Castiglione F, D'Incà R, Orlando A, Festa S, Riegler G, Fries W, Meucci G, Alvisi P, Mocciaro F, Papi C, Mossa M, Sena G, Guidi L, Testa A, Renna S, Frankovic I, Viola A, Patturelli M, Chiaramonte C, Biancone L, On Behalf Of Ig-Ibd Italian Group For The Study Of Inflammatory Bowel Disease. Incident Colorectal Cancer in Inflammatory Bowel Disease. Cancers (Basel). 2022 Jan 30;14(3):721. doi: 10.3390/cancers14030721.PMID: 35158989 217. Lenti MV, Scribano ML, Biancone L, Ciccocioppo R, Pugliese D, Pastorelli L, Fiorino G, Savarino E, Caprioli FA, Ardizzone S, Fantini MC, Tontini GE, Orlando A, Sampietro GM, Sturniolo GC, Monteleone G, Vecchi M, Kohn A, Daperno M, D'Incà R, Corazza GR, Di Sabatino A. Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease. Front Med (Lausanne) 2023 Apr 11;10:1031998. doi: 10.3389/fmed.2023.1031998. 218. Salvatori S, Marafini I, Franchin M, Lavigna D, Brigida M, Venuto C, Biancone L, Calabrese E, Giannarelli D, Monteleone G Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases. J Clin Med. 2023 Apr 3;12(7):2658. doi: 10.3390/jcm12072658. 219. Macaluso FS, Papi C, Orlando A, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology. Dig Liver Dis. 2023 Apr;55(4):442-453. doi: 10.1016/j.dld.2023.01.155. Epub 2023 Feb 13.PMID: 36792429 220. Neri B, Mossa M, Salvatori S, Appolloni V, Pensa C, Lambiase S, Lolli E, Calabrese E, Monteleone G, Bianchi L, Campione E, Biancone L Hidradenitis suppurativa and inflammatory bowel disease in a nested case-control study. Dig Liver Dis. 2023 Apr;55(4):490-495. doi: 10.1016/j.dld.2022.10.016. Epub 2022 Nov 9. PMID: 36371384 221. Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22.PMID: 36152897. 64/68 222. Amiot A, Rahier JF, Baert F, Nahon S, Hart A, Viazis N, Biancone L, Domenech E, Reenears C, Peyrin-Biroulet L, Beaugerie L, Burisch J; I-CARE collaborator group. The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study. J Crohns Colitis. 2023 Jan 27;17(1):37-48. doi: 10.1093/ecco-jcc/jjac091.PMID: 35767639 223. Conigliaro P, D'Antonio A, Wlderk A, Sabuzi F, Ferraioli M, Sichi L, Da Ros V, Biancone L, Bergamini A, Sole Chimenti M. Clinical and imaging findings in enteropathic spondyloarthritis with special emphasize in diagnostic delay: a cross-sectional study. Ther Adv Chronic Dis. 2024 Feb 19;15:20406223241229843. doi: 10.1177/20406223241229843. 224.Fatica M, Monosi B, Conigliaro P, D'Antonio A, Essofi S, Cuccagna E, Bergamini A, Biancone L, Monteleone G, Triggianese P, Calabrese E, Chimenti MS. Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases. RMD Open. 2024 Jan 31;10(1):e003820. doi: 10.1136/rmdopen-2023-003820.PMID: 3829680 225. Neri B, Mancone R, Savino L, Schiavone S, Formica V, Pizzi F, Salvatori S, Mossa M, Migliozzi S, Fiorillo M, Morelli C, Moscardelli A, Lolli E, Calabrese E, Sica GS, Monteleone G, Biancone L. Mucinous and Signet-Ring Cell Colonic Adenocarcinoma in Inflammatory Bowel Disease: A Case-Control Study. Cancers (Basel). 2023 Jul 26;15(15):3803. doi: 10.3390/cancers15153803.PMID: 37568619 226. De Cristofaro E, Lolli E, Migliozzi S, Sincovih S, Marafini I, Zorzi F, Troncone E, Neri B, Biancone L, Del Vecchio Blanco G, Calabrese E, Monteleone G. Frequency and Predictors of Dysplasia in Pseudopolyp-like Colorectal Lesions in Patients with Long-Standing Inflammatory Bowel Disease. Cancers (Basel). 2023 Jun 27;15(13):3361. doi: 10.3390/cancers15133361. 227. Bezzio C, Vernero M, Costa S, Armuzzi A, Fiorino G, Ardizzone S, Roselli J, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Alimenti E, Balestrieri P, Ricci C, Cappello M, Felice C, Coppini F, Alvisi P, Di Luna I, Gerardi V, Variola A, Mazzuoli S, Lenti MV, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)’s COVID-19 Study Group (Biancone L in the Study Group,PubMed). SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves. BMC Gastroenterol. 2023 Jul 5;23(1):230. doi: 10.1186/s12876-023-02841-0. 228. Neri B, Russo C, Mossa M, Martire FG, Selntigia A, Mancone R, Calabrese E, Rizzo G, Exacoustos C, Biancone L. High Frequency of Deep Infiltrating Endometriosis in Patients with Inflammatory Bowel Disease: A Nested Case-Control Study. Dig Dis. 2023;41(5):719-728. doi: 10.1159/000530896. Epub 2023 Jun 30. 229. De Cristofaro E, Montesano L, Lolli E, Biancone L, Monteleone G, Calabrese E, Zorzi F. Echopattern parameter as an aid to profile Crohn's disease patients. Dig Liver Dis. 2023 Dec;55(12):1652-1657. doi: 10.1016/j.dld.2023.05.018. Epub 2023 May 29. 65/68 230. Sica GS, Sensi B, Siragusa L,Blasi F,Crispino B,Pirozzi B, Angelico R, Biancone L, Khan J. Surgical management of colon cancer in ulcerative colitis patients with orthotopic liver transplant for primary sclerosing cholangitis. A systematic review. Eur J Surg Oncol. 2023 Oct;49(10):106922. doi: 10.1016/j.ejso.2023.04.021. Epub 2023 May 231. Fatica M, Monosi B, Conigliaro P, D'Antonio A, Essofi S, Cuccagna E, Bergamini A, Biancone L, Monteleone G, Triggianese P, Calabrese E, Chimenti MS. Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases. RMD Open. 2024 Jan 31;10(1):e003820. doi: 10.1136/rmdopen-2023-003820. PMID: 38296800 232. Arpa G, Vanoli A, Antoci F, Lenti MV, Di Sabatino A; and the Small Bowel Carcinoma Consortium. A Clinicopathologic Comparison Between Early-Onset and Late-Onset Small Bowel Adenocarcinoma: A Multicenter International Study. (Biancone L included in the Study Group, see PubMed.) Am J Gastroenterol. 2024 Jan 1. doi: 10.14309/ajg.0000000000002585. Online ahead of print. PMID: 3796609 233. Neri B, Mancone R, Savino L, Schiavone S, Formica V, Pizzi F, Salvatori S, Mossa M, Migliozzi S, Fiorillo M, Morelli C, Moscardelli A, Lolli E, Calabrese E, Sica GS, Monteleone G, Biancone L. Mucinous and Signet-Ring Cell Colonic Adenocarcinoma in Inflammatory Bowel Disease: A Case-Control Study. Ca